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REVIEWS OF CHROMOSOME STUDIES IN UROLOGICAL TUMORS 
CYTOGENETICS AND GENES IN TESTICULAR TUMORS
AVERY A. SANDBERG, AURELIA M. MELONI a n d  RON F. SUIJKERBUIJK*
From the Southwest Biomedical Research Institute and Genetrix, Inc., Scottsdale, Arizona
ABSTRACT
Purpose: We reviewed available cytogenetic and m olecular findings in  testicu lar germ  cell 
tum ors, and their possible application to clinical, pathological and basic param eters.
M aterials and Methods: Findings in the lite ra tu re  on testicu la r germ  cell tum ors as well as 
those from our laboratory were summarized, including a lis ting  of the cytogenetic findings on 
testicu lar germ cell tumors to date with some illustrations,
Results: Testicular germ cell tumors are characterized in  m ost cases by the presence of an 
i(12p) isochromosome. In tumors w ithout such an abnorm al chromosome studies using fluores­
cence in  situ  hybridization and molecular approaches have dem onstrated  either m asking of the 
i(12p) or the presence of extra 12p sequences in the karyotype. A lthough testicu lar germ  cell 
tum ors are often associated with chromosome changes in  addition to the i(12p), no other 
specifically recurrent structural chromosome changes have been  found. B ased on th e  cytogenetic 
and molecular findings in testicular germ cell tum ors, a hypothetical scheme for the  genetic 
events leading to these tum ors is presented.
Conclusions: The genetic events leading to genesis of tes ticu la r germ  cell tum ors in  m en appear 
to be related  to aneuploidization followed by the form ation of an  i(12p) isochromosome, th e  la tte r  
characterizing the preponderant num ber of testicu lar germ  cell tum ors. The exact role of the 
i(12p) isochromosome in testicular germ cell tum or pathogenesis rem ains to be determ ined, as is 
true  of the genes involved in or affected by these tum ors. B ased on presen tly  available inform a­
tion, a hypothetical pathogenetic and oncogenetic model for th e  developm ent of testicu lar germ  
cell tum ors is presented.
Key Words: testicular neoplasms, germ cells, cytogenetics
It is well established that the occurrence of clonal, acquired 
chromosomal (karyotypic or cytogenetic) aberrations is a 
characteristic feature of neoplastic cells, and that these ab­
normalities may not only be useful clinically in the diagnosis 
and prognosis of various disease states but they may also 
reflect the molecular mechanisms underlying the process of 
tumor initiation and progression. The recognition of recur­
ring and highly specific chromosomal aberrations, such as 
deletions, translocations and inversions, is a cardinal requi­
site for the identification and isolation of cancer relevant 
genes (that is, proto-oncogenes, tumor suppressor genes and 
deoxyribonucleic acid [DNA] repair genes) at or near the 
rearranged chromosomal sites,
We present the cytogenetic findings described in germ cell 
tumors of the testis, clinical (however limited) and patholog­
ical applications, the role of these cytogenetic changes in 
pathogenesis of testicular germ cell tumors and the molecu­
lar genetics of these tumors. The latter subject, which in­
cludes fluorescence in situ hybridization studies, molecular 
characterization of the i(12p) iso chromosome, studies on tu­
mor suppressor genes and proto-oncogenes, genomic imprint­
ing and an oncogenetic model, was given much attention in 
our review, since this area has not been evaluated as much as
Human germ cell tumors are a heterogeneous group of 
neoplasms tha t occur in the testis and ovary, and at extra- 
gonadal sites.1“3 Two main entities may be distinguished. 
One entity includes tumors composed of neoplastic germ, 
cells, called seminoma in the testis, dysgerminoma in the 
ovary and germinoma at extra-gonadal sites. These tumors 
are indistinguishable with respect to histological findings, 
immunohis to chemistry and ultrastructure, that is they all 
show diffuse, membranous staining of the tumor cells with 
placental-like alkaline phosphatases.4 This and many other 
characteristics are shared by carcinoma in situ of the testis, 
which is believed to be the neoplastic counterpart of gono­
cytes.4 For this reason it has been proposed that tumors 
composed of neoplastic gonocytes should be called gonocyto­
mas.5 The other entity consists of nonseminomatous germ 
cell tumors, which are composed of neoplastic embryonic 
tissues (embryonal carcinoma, immature teratoma and ma­
ture teratoma) and/or extraembryonic tissues (yolk sac tumor 
and choriocarcinoma). Nonseminomatous germ cell tumors 
may have a semino matous component. According to the British 
classification such lesions are called combined tumors.6 Patho­
genesis, histological composition, cytogenetics, ploidy and de­
gree of malignancy of germ cell tumors differ, in some cases 
bearing a possible relationship to anatomical site of the tumor, 
and age and sex of the patient.
Testicular germ cell tumors are heterogeneous.7,8 Epide­
chromosome changes.
;|î Current address: Department of Human Genetics, University 
Hospital, Nijmegen, The Netherlands.
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miologically, 3 groups of testicular germ cell tumors can be 
distinguished: 1) infantile tumors, 2) tumors of adolescents 
and young adults, and 3) tumors of elderly men. Most infan­
tile testicular germ cell tumors have the histological appear­
ance of yolk sac tumor.9 Tumors in adults can he divided into 
seminomas (approximately 50% of the cases) and nonsemi­
nomatous lesions (approximately 40%). A smaller percentage 
of cases combines seminoma and nonseminomatous compo­
nents. Testicular germ cell tumors in elderly men have the 
histological appearance of spermatocytic seminoma. These 
tumors are negative for placental-like alkaline phosphatase4 
and are not composed of gonocytes but of more mature germ 
cell precursors, and they are usually diploid.10
Most testicular germ cell tumors in adults are associated 
with carcinoma in situ, composed of neoplastic gonocytes, as 
precursor lesions. Often carcinoma in situ can be found in the 
testicular parenchyma surrounding the invasive cancer. In­
fantile testicular tumors lack carcinoma in situ.11 The same 
is true of spermatocytic seminoma, although intratubular 
spermatocytic seminoma has been demonstrated.12 Thus, ex­
cept for infantile tumors and spermatocytic seminoma, germ 
cell tumors of the testis are probably derived from dysplastic 
germ cell precursors (gonocytes). Carcinoma in situ appears 
to be the common precursor for seminomas and nonsemino­
matous testicular germ cell tumors.5
Testicular cancers represent approximately 1 to 2% of all 
malignant tumors in men and are the most common malig­
nancy in young men.13 Approximately 95% of these lesions 
are testicular germ cell tumors. The residual group of testic­
ular tumors consists predominantly of gonadal stromal tu­
mors. During the years the incidence of testicular cancer has 
increased.14»15 Patient age a t presentation ranges from ap­
proximately 20 to 55 years, depending on the histological 
type.16 At presentation, patients with seminomas are gener­
ally older (median age 40 years) compared to those with 
nonseminomas (median age 25 years), whereas patients with 
combined tumors usually are of intermediate age (median 
age 30 years).16,17
Klinefelter’s syndrome, X-linked XY gonadal dysgenesis, 
testicular carcinoma in situ, the Li-Fraumeni syndrome and 
prior testicular germ cell tumors are known risk factors for 
the development of germ cell tumors of the testis.18-20 Even 
though metastatic testicular germ cell tumors are responsive 
to chemotherapy, approximately 15% of these tumors become 
resistant to this therapy resulting in premature death. Germ 
cell testis tumors, especially embryonal carcinoma, have the 
potential to differentiate into the 3 germ layers, express 
tumor markers, such as ß-human chorionic gonadotropin and 
«-fetoprotein, and respond to the effects of differentiating 
a gents.'21
Testicular germ cell tumors are divided into 2 main groups 
(seminomas and nonseminomas) based on clinicopathological 
characteristics.22 The seminomas, originating from premei- 
otic germ cells, are subdivided into classical and anaplastic 
tumors, those with syncytiotrophoblastic giant cells and 
spermatolytic seminomas. Spermatocytic seminoma, origi­
nating from more mature germ cells than the other forms of 
seminoma, is considered a separate entity for pathogenetic, 
clinical and histochemical reasons.23“25 Nonseminomas, orig­
inating from embryonic or extraembryonic tissues, are sub­
divided histologically into embryonal carcinoma, yolk sac 
tumor (endodermal sinus tumor), choriocarcinoma and tera­
toma, In most cases all of these tumors consist of more than 
1 histological component.26 The morphological characteris­
tics of the different histological components were described 
by Mostofi.22
ISOCHROM OSOM E 12P, A GENETIC HALLMARK IN
TESTICULAR GERM CELL TUMORS
A recurrent and characteristic chromosome anomaly in 
testicular germ cell tumors of all histological types and at any 
site is the presence of an i(12p) isochromosome (figs. 1 and 2) 
in more than 80% of the cases (see Appendix).27-50 This 
isochromosome consists essentially of 2 chromosome 12 short 
arms, and it also has been described in rare lesions derived
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F ig . 1. G-banded karyotype of testicular germ cell tumor shows 2 i(12p) isochromosomes (arrowheads), characteristic finding in all types 
of these tumors. Number of i(12p) isochromosomes may vary from 1 to more than 4. Extra chromosomes are present in several groups, 
in eluding X (1 abnormal) and Y chromosomes. Total number of chromosomes is 60. Presence of extra X chromosome accounts for appearance 
of sex-chromatin body often observed in testicular germ cell tumor.
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Fig. 2. Most common and characteristic chromosomal anomaly 
present in testicular germ cell tumor, that is isochromosome for short 
arm of chromosome 12 ( il2p).
from malignant differentiation in mediastinal (or ovarian) 
nonseminomas, such as acute leukemia, embryonal rhabdo­
myosarcoma and neuroepithelioma.32-53 The i(12p) isochro­
mosome may constitute the only structural cytogenetic 
anomaly in primary and metastatic testicular germ cell tu­
mors.27’28»34'52
The first report on the presence of an i(12p) isochromosome 
in testicular germ cell tumors was that of Atkin and Baker in 
1982.52»53 Since then many studies have confirmed this find­
ing, placing this cytogenetic change as highly specific for 
germ cell tumors of all histological varieties and in vari­
ous organs in male and female patients. How the chromo­
somal change resulting in formation of the abnormal 
chromosome contributes to the neoplastic phenotype is pres­
ently unknown. Questions have been raised whether an ef­
fect of the i(12p) isochromosome could be due to amplification 
of normal or modified genes on this abnormal chromosome, or 
concomitant loss of the 12q segment. Testicular germ cell 
tumors in adults without the i(12p) isochromosome show 
marker chromosomes of different morphology with each con­
taining part of chromosome 12.35 In testicular germ cell tu ­
mors without an i(12p) isochromosome extra copies of 12p 
segments are incorporated into marker chromosomes that 
could not be resolved by banding analysis. A comparison of 
tumors positive and negative for the i(12p) isochromosome 
showed that the only significant difference consisted of more 
rearrangements affecting the 12pl3 segment and extra cop­
ies of the 12p segment in the negative group.36 It appears 
that testicular germ cell tumors negative for the i(12p) iso­
chromosome do not differ clinically or pathologically from the
more numerous tumors positive for this isochromosome.’^  
The number of copies of the i(12p) isochromosome in the 
tumor may act as a prognostic indicator,54 with more than 3 
copies being associated with tumor progression and a greater 
probability of treatment failure.55"58
Studies have shown that testicular germ cell tumors and 
their cell lines with and without an i(12p) isochromosome 
frequently contained other 12p anomalies that ranged in 
complexity from simple trans lo cations of most of the arms to 
multi-way, insertional rearrangements that could not be 
fully characterized.32’59 Thus, testicular germ cell tumors 
positive and negative for the i(12p) isochromosome have a 
greater than normal number of copies of the entire or parts of 
the 12p arm.
Some have argued that i(12p) isochromosome formation 
must be preceded by an aneuploidization event during the 
early stages of tumor development.60’61 Others have sug­
gested that in testicular germ cell tumors the i(12p) isochro­
mosome may originate from a translocation or as a nonsister 
chromatid exchange.62 Molecular studies have shown that 
the i(12p) isochromosome constitutes a genuine isochromo­
some with genetically identical arms, and most likely origi­
nates from a misdi vision of the centromere rather than from 
a translocation or a nonsister chromatid exchange.61
STRUCTURAL AND NUM ERICAL CHROMOSOME CHANGES IN 
TESTICULAR GERM CELL TUM ORS OTHER THAN TH E I(12P)
ISOCHROMOSOME
Cytogenetic analysis of tumors requires dividing cells in 
prometaphase or metaphase for optimal analysis. To obtain a 
sufficient number of such dividing cells, the tumor material 
must be cultured in vitro for several days.53 The advantages 
of cytogenetic analysis of testicular germ cell tumors are that 
the number and identity of the chromosomes can be estab­
lished in each cell, minor variations from cell to cell may be 
ascertained, derivation of abnormal chromosome (markers) 
can be deciphered and photographic records of the cells ex­
amined may be readily obtained. The disadvantages are re­
lated to inability of cytogenetic analysis to recognize chromo­
some changes in interphase (nondividing) cells, and the 
significant time and effort expended in such an analysis.
Chromosome numbers in seminomas are more homoge­
neous than those in nonseminomas, with triploid and tet- 
raploid numbers being common in the former and hyper­
diploid to hyper-triploid counts being common in the latter 
(fig. 3 and Appendix).27-50’63 In addition, i(12p) isochromo­
some copies tend to be more numerous in nonseminomaa 
than in seminomas. These differences are in themselves in-
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F ig . 3. Modal chromosome numbers of 6 malignant teratomas, 16 
seminomas and 4 combined testicular germ cell tumors. Each class 
represents 5 chromosome numbers (45 tó 49, 50 to 54 and so forth). 
Findings shown are in keeping with general experience with chro­
mosome numbers in various subtypes of testicular germ cell tumor. 
Data from study of Atkin and Balter .fi3
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sufficient to differentiate between these 2 groups of testicular 
germ cell tumors. There are no structural cytogenetic 
changes that characterize any group of these tumors.64 Pro­
gression of testicular germ cell tumors may be associated 
with many cytogenetic changes, some more frequent than 
others, consisting of loss of chromosomes 5, 11, 13 and 18, 
and gain of chromosomes X, 7, 8 and 12. Multiplication of the 
i(12p) isochromosome also occurs in tumor progression.
Loss of certain chromosomes or loss of heterozygosity for 
chromosomal regions is important for the development of 
malignancy, presumably because of loss of genes with tumor 
suppressing and differentiation regulating properties.65-68 If 
loss of chromosomes in testicular germ cell tumors is related 
to loss of genes crucial for normal cell differentiation, differ­
ent chromosomes should be underrepresented in nonsemino­
matous testicular germ cell tumors compared to seminomas. 
However, because both are germ cell tumors it is not surpris­
ing that some chromosomes are underrepresented in both 
subtypes.64
Structural changes common to all types of testicular germ 
cell tumors in addition to the i(12p) isochromosome affect (in 
the order of frequency) the 12p, 17q, Ip, lq, 9q, 22q, 6q and 
7p regions. However, none of the karyotypic changes gener­
ated is sufficiently recurrent to deserve the attention re~ 
quired by the i(12p) isochromosome. Deletions of lp36 may 
have value as a prognostic marker in pediatric testicular 
germ cell tumors without the i(12p) isochromosome,69 
Rodriguez et al found the number of i(12p) iso chromosomes 
to be greater in nonseminomas than seminomas, and more 
common re arrangements of the lp32—»36 and 7q ll regions in 
teratomas and of the lp22 region in yolk sac tumors than in 
the other types of testicular germ cell tumors.32 Cytological 
evidence of gene amplification in the form of hsr and/or dmin 
were detected in one-fourth of all extra-gonad al, mostly met­
astatic, lesions, suggesting that amplification of genes is 
important in disease progression. The gene of importance is 
not known.33 Rearrangements predominated in regions lp ll , 
12pll, 12q24 and 17, in the form of an i(17q) isochromosome 
in seminomas, whereas nonseminomas showed involvement 
of lp32-»36, l q l l—»22, 7 p ll—>22 and 17q25 regions with a 
deletion of 12ql3-»q22.32 An interesting observation was 
that testicular germ cell tumors resulting in cytogenetic fail­
ure were more likely to respond to therapy than those with 
chromosome abnormalities.70 The presence of demonstrable 
sex chromatin bodies in testicular germ cell tumors of the testis, 
once karyotyping of such tumors was accomplished, was due to 
extra X chromosomes in a substantial number of cases.53
PATHOGENETIC MODELS
In a review of the pathogenesis of testicular germ cell 
tumors based on a cytogenetic model, de Jong et al evaluated 
the chromosome data in the literature as well as their own 
data, and presented their concepts of the genesis and pro­
gression of these tumors.68 They believed the data to support 
the theory that seminomas and nonseminomas may have a 
single origin and a common neoplastic pathway. For com­
bined tumors, with both components separately karyotyped 
using banding techniques,37-38’71 both components had clonal 
abnormalities in common, although in 1 case36 the only struc­
tural abnormality in both components was an i(12p) isochro­
mosome.38 In 2 macroscopic ally distinguishable components 
of a human testicular germ cell tumor, resembling a semi­
noma and an embryonal carcinoma, Walt et al reported 2 
similar marker chromosomes, indicating the common ori­
gin.72 These karyotypic data support the model in which 
nonseminomatous testicular germ cell tumors progress 
through a seminoma stage.
An interpretation of the cytogenetic findings in relation to 
the pathogenesis of testicular germ cell tumors was pre­
sented by Rodriguez et al, who found that some of these
tumors were near diploid or hyper-diploid.32 This interpreta­
tion is at variance with the evolutionary scheme favored by 
de Jong et al in which cell fusion or polyploidization is the 
first event in neoplastic transformation.64 These simple nu­
merical derivations are better explained by stipulating that 
nondisjunctions occur in diploid or pseudo-diploid cells. Thus, 
Rodriguez et al favored a model of testicular germ cell tumors 
in which early saltatory numerical changes have a less prom­
inent pathogenetic role32 than in the scheme proposed by de 
Jong et al,64 and they interpreted their data as consistent 
with the loss of a putative tumor suppressor gene on the 12q 
region as the initial change. Some of these issues are further 
discussed in our sections on molecular genetic studies in 
testicular germ cell tumors. Thus, suggested pathways for 
the development of aneuploidy in testicular germ cell tumors 
may involve successive nondisjunction of a diploid cell, aneu- 
ploidization, or polyploidization cell fusion followed and/or 
preceded by chromosomal gains or losses.
Carcinogenesis of testicular germ cell tumors probably be­
gins during intrauterine life. An early event may be 
polyploidization of a dysplastic germ cell precursor leading to 
carcinoma in situ with a hyper-triploid or peri-tetraploid 
chromosome number with few structural abnormalities. An­
other early event is the formation of the i(12p) isochromo­
some. In tumors without an i(12p) isochromosome other 
structural changes of chromosome 12 may be substituted.
The initial stage that may be reached in this progression of 
carcinoma in situ is the development of a seminoma (in 50% 
of the cases the neoplastic pathway ends at this point). The 
tumor at this stage may proceed along the same line of 
differentiation into an invasive seminoma, in which the cells 
resemble gonocytes, as they do in carcinoma in situ. They 
have similar ultrastructural features, both express placental- 
like alkaline phosphatase and they have similar DNA index 
values (higher than in nonseminomas).73 Seminomas are less 
aggressive than nonseminomas, appear earlier in the clonal 
evolution of testicular germ cell tumors and become clinically 
manifest at an older patient age, with most of the tumors 
being stage I. In the other 50% of these tumors progression of 
carcinoma in situ to nonseminomas is associated with loss of 
chromosomes 15 and 22 and the appearance of copies of the 
i(12p) isochromosome relative to those in seminomas, with 
loss of gonocytic differentiation (fig. 4). Thus, nonseminomas 
represent more advanced cancers than seminomas in terms 
of tumor evolution. Nonseminomas, being more aggressive, 
become manifest at a young patient age. Patients with com­
bined tumors present at an age between that of patients with 
seminomas and nonseminomas.
In essence, 2 models show the pathogenetic relationship 
between seminomas and nonseminomatous testicular germ 
cell tumors.69*74 One model assumes that seminomas and 
nonseminomatous tumors derive independently from trans­
formed (dysplastic) intratubular germ cells through carci­
noma in situ. The histogenesis of seminomas diverges from 
that of the other testicular germ cell tumors at an early 
stage.75"77 The 2 neoplastic pathways are distinct with no or 
only limited crossover and represent either a caricature of 
embryogenesis or abortive spermatogenesis.78 The other 
model suggests that all testicular germ cell tumors in adults 
(with the possible exception of spermatocytic seminoma12 
and infantile testicular germ cell tumors) have a single origin 
with 1 neoplastic pathway on which seminomas represent an 
intermediate stage in development of nonseminomatous 
germ cell tumor components.77,79 According to this view sem­
inomas and nonseminomatous testicular germ cell tumors 
might be expected to show a close relationship.
It is evidently more difficult to fit infantile yolk sac tumor 
into the proposed carcinoma in situ model. Of 10 tumors 3 
were diploid so that apparently polyploidization is not obli­
gate. When polyploidization has occurred the DNA index of 
the tumors remains close to 2, in keeping with a short period .
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FIG. 4. Hypothetical genetic events involved in genesis of testicular germ cell tumor. Note key role of carcinoma in situ (CIS) in pathway 
toward genesis of seminomas and nonseminomas. Genesis involves net loss of DNA at various steps. Some genes (CKIT , SCF , NMYC, 
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of tumor evolution in young patients. The relatively low 
malignant potential of the tumors is reflected by the high 
proportion of patients with stage I disease.80 The entirely 
different histological composition of testicular germ cell tu­
mors in infants compared to that in adults may be explained 
by epigenetic factors in the infantile testis.81,82 The patho­
genesis of testicular germ cell tumors in infants also may be 
fundamentally different from that in adults because carci­
noma in situ could not be demonstrated in the vicinity of 
infantile yolk sac tumors.11 However, carcinoma in situ is 
found in a high proportion of testes containing germ cell 
tumor in adults,83’84 except for spermatocytic seminoma.82 
Additional evidence for a different pathogenesis may be the 
occurrence of diploid tumors, and the absence of the i(12p) 
marker chromosome in the only infantile yolk sac tumor that 
has been karyotyped.39 The pathogenesis of spermatocytic 
seminoma also may be different. As mentioned, these diploid 
tumors are negative for placental-like alkaline phosphatase4 
and are not composed of gonocytes but of more mature germ 
cell precursors.
de Jong et al believed that the data on ploidy and cytoge­
netics of seminoma and nonseminomatous testicular germ 
cell tumors fit into the pathogenetic model in which all 
germ cell testis tumors in adults progress through a semi­
noma stage.64 If this model is correct it will offer a system to 
study germ cell activation, that is the switch from a highly 
specialized germ cell to a pluripotent embryonal cell. A com­
parative study of the 2 tumor types may show which chro­
mosomes harbor genes important for differentiation, which 
chromosomal events are necessary for oncogenesis and tumor 
progression, and which oncogenetic steps are common or 
different for various testicular germ cell tumors.
FLUORESCENCE IN SITU HYBRIDIZATION
Fluorescence in situ hybridization enables sensitive detec- 
:ion and localization of specific nucleic acid sequences in 
morphologically preserved biological structures, such as 
chromosomes, cells and (archival) tissues.85 Due to world­
wide efforts in the context of the Human Genome Project to 
levelop high resolution physical maps of all individual chro­
mosomes, a rapidly increasing number of chromosome spe­
cific DNA probes is presently available to highlight and iden­
tify single chromosomes (by chromosome painting)86 or 
segments of chromosomes in dividing and nondividing cells. 
Moreover, the development of multicolor fluorescence in situ 
hybridization procedures has opened the possibility to detect 
simultaneously several target sites on individual chromo­
somes.87"90 Fluorescence in situ hybridization allows rapid 
and reliable identification of (marker) chromosomes in cyto- 
logical preparations regardless of their origin or accessibility 
for conventional cytogenetic techniques. Therefore, fluores­
cence in situ hybridization can be used as a molecular means 
to provide additional, detailed karyotypic information that 
otherwise would remain undetected. Furthermore, the tech­
nique can provide an initial clue in the identification and 
characterization of chromosomal subregions involved in tu­
mor specific chromosomal abnormalities at a resolution be­
yond conventional cytogenetic microscopy.
CHROMOSOME 12 ABNORMALITIES IN TESTICU LA R  GERM
CELL TUMORS
Fluorescence in situ hybridization studies on testicular 
germ cell tumors and their derived cell lines were mainly 
aimed at the presence of chromosome 12 abnormalities, es­
pecially the i(12p) isochromosome (figs. 5 to 8).47>91 These 
figures show the use of fluorescence in situ hybridization to 
demonstrate 12p sequences in testicular germ cell tumors 
without an i(12p) isochromosome. Thus, figure 5 is a repre­
sentative karyotype from a testicular germ cell tumor with 
an abnormal chromosome 12 but not an i(12p) isochromo­
some, in addition to 2 normal chromosomes 12. Figures 6 to
8 show the results obtained by fluorescence in situ hybrid­
ization and comparative genomic hybridization analyses us­
ing several specific probes for chromosome 12 to demonstrate 
the presence of 12p sequences in the abnormal (marker) 
chromosomes. The frequent observation of an i(12p) iso chro­
mosome in all types of testicular germ cell tumors (that is 
testicular, ovarian and extra-gonadal) and its limited occur­
rence in solid neoplasms other than testicular germ cell tu ­
mors (found in 4 isolated cases only45-92-95) demonstrated its
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F i g . 5. G-banded karyotype of testicular germ cell tumor containing number of numerical and structural changes,47 Noteworthy is absence 
of i(12p), which is characteristic finding in more than 80% of testicular germ cell tumors, but presence of abnormal large chromosome 12 
marker. Fluorescence in situ hybridization studies (see figs, 7 and 8) showed overrepresentation of 12p sequences. Arrowheads show extra 
or abnormal chromosomes in karyotype in addition to chromosome 12 marker, which contained 58 chromosomes. Note extra X chromosome.
specificity for these tumors. Rapid and reliable detection 
and/or verification of this chromosome in dividing as well as 
nondividing tumor germ cells is diagnostically useful.55 
Moreover, there is consensus that its presence correlates 
with the malignant character of the lesion30-47-55-58 and it is 
believed that the presence and copy number of the i(12p) 
iso chromo some may also serve as prognostic markers for 
germ cell testis tumors.55-57 However, despite numerous cy­
togenetic studies on testicular germ cell tumors little is 
known about the exact nature and role of the i( 12p) isochro­
mosome in tumor development.
Fluorescence in situ hybridization studies using DNA 
probes specific for the entire chromosome 12 and the 12p arm 
(mostly in combination with a chromosome 12 centro me rie 
probe) allowed identification of the i(12p) iso chromo some, 
and demonstrated its genuine iso chromo som al character in 
several testicular96-97 and nontesticular97"101 germ cell tu­
mors. Furthermore, marker chromosomes, partly consisting 
of the 12p region and cytogenetically unidentified, were 
noted to occur in testicular germ cell tumors positive for an 
i(12p) isochromosome. 97>98 In another study the recognition 
of an i(12p) isochromosome in dividing and nondividing tu­
mor germ cells was achieved by using a chromosome 12 
centromeric alphoid probe only.62 Its presence could be as­
sessed from the size of the fluorescent signals in the nuclei, 
which is significantly different for i(12p) isochromosomes 
(that is smaller or larger) than for the normal chromosome 12 
homologues.62-102 Although this latter approach is informa­
tive and of diagnostic value even in nondividing tumor germ 
cells,, it is clear that other chromosomal abnormalities involv­
ing the 12p region (but not its centromeric region) will re­
main undetected.
The application of similar fluorescence in situ hybridiza­
tion strategies that allow detection of chromosome 12 derived 
sequences, especially the 12p region, in testicular germ cell 
tumors without an i(12p) isochromosome revealed the pres­
ence of multiple copies of almost an entire 12p arm (mostly as 
tandem duplications) in all 22 tumors examined.36-47-48-91-96-97 
Again, the majority of these 12p arm abnormalities remained 
un discerned using conventional cytogenetic techniques, a 
finding that previously suggested that testicular germ cell 
tumors with and without an i(12p) isochromosome may rep­
resent different subtypes of these tumors with different clin­
ical and pathological aspects.103 The consistent overrepresen­
tation of 12p sequences in testicular germ cell tumors 
positive and negative for the i(12p) isochromosome indicates 
a common mechanism leading to malignancy in these tu­
mors.30*47 The invariable multiplication of almost the entire 
12p arm in testicular germ cell tumors implies the involve­
ment of genes present along the length of the 12p region that 
may be important in tumor development (for example malig­
nant potential, growth advantage, tumor progression and 
therapy resistance) 47>55*104 However, the absence of nonran­
dom involvement of any 12p subregion as observed in these 
tumors hampered the identification and further analysis of 
such genes.59
Recently, the identification and preliminary characteriza­
tion of a 12p derived amplicon, found in a metastatic semi­
noma without an i(12p) isochromosome, were reported.91 
More precisely, fluorescence in situ hybridization (using 12p 
region specific painting probes)105 and comparative genomic 
hybridization analyses (the latter providing information on 
overrepresentation and underrepresentation of chromosomes 
or chromosomal segments in whole tumor genomes)91*106'107 
revealed the amplification of subregion 12pll.2p-pl2.1 
within the tumor genome, which occurred as an abnormally
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Fig. 6 . Amplification of chromosome 12pl 1.2-12.1 region in metastasis of i(12p)-negative seminoma. Karyotype of tumor contained several 
abnormalities, including derivative chromosome 12 with large amount of additional material on short arm, add(12p), and derivative 
chromosome 17 with additional material on long arm, add(17q), Studies addressed nature of extra materials on these abnormal chromosomes 
and were revealed to be predominantly of 12p origin in add(12) and add(17) but not in other abnormal chromosomes. Results were obtained 
from fluorescence in situ hybridization and comparative genomic hybridization analyses.91 A, chromosome 12-speciflc library pBS-12 (green) 
and 12-centromeric probe pal2H8 (red) hybridized onto tumor-derived metaphase spread reveals copies of normal chromosome 12 (arrows), 
add(17) chromosome (small arrowhead) and add(12) chromosome (large arrowhead). Chromosomes are counterstained in blue. Add(17) 
consists of chromosome 17 material but mostly of chromosome 12 material added onto 17q (small arrowhead). Add(12) appears to be 
composed almost entirely of 12p material except for its distal part (large arrowhead^ whose origin is unknown. B, further hybridization 
studies were done with chromosome 12p-specific paint probe M28 (green) in combination with chromosome 12 centromeric probe p«12H8 
(red). As in part A, study demonstrated that add(17) contained 12p-positive material only (small arrowhead) and that add(12) contained extra 
12p segments over its entire length (large arrowhead). Only 1 normal chromosome 12 (arrow) is present in this metaphase sample. C, 
hybridization of 12p-specific (region 12pll.2-12.1) YAC 5 onto tumor derived metaphase chromosomes (signals in yellow). Note that add(17) 
chromosome shows 3 regions of hybridization (small arrowhead), whereas add(12) chromosome reveals multiple hybridization sites (large 
arrowhead). Normal 12 homologues show single spots (arrows). For contrast, chromosomes are shown in red. Multiple but not contiguous 
copies of YAC 5 hybridizing DNA sequences are present in additional segments (arrowheads). D , tumor derived interphase nuclei hybridized 
with YAC 5 show multiple hybridization signals in yellow. Approximately 25 to 35 double spots (each representing 1 hybridizing locus) can 
be observed per area. E, representative comparative genomic hybridization result with differently labeled tumor (red) and reference (69, XXY; 
green/yellow) DNAs onto normal human metaphase spread (46, XY). Chromosomes are counterstained in blue. Red signals are visible on 
short arm of both chromosome 12 homologues (arrowheads). F, comparative genomic hybridization analysis on 1 chromosome 12 hom ologue 
shown in part E. Measured intensity profiles for tumor and refez'ence DNA are represented by red and green lines, respectively. Blue line 
represents comparative genomic hybridization, that is tumor-versus-normal DNA ratio profile. Over representation of 12p sequences in tumor 
DNA can easily be discerned (peak value at 12pll.23),
banding region (abr gene) in a cytogenetically abnormal chro­
mosome 12. Taldng into consideration the association be­
tween the i(12p) isochromosome (that is an increase in copy 
number of 12p derived sequences) and malignancy (that is 
tumor progression) in testicular germ cell tumors, as well as 
the fact that genomic amplifications occurring during solid 
tumor progression usually involve proto-oncogenes,108 it was 
assumed that amplicons associated with genes in this 12p 
subregion were specifically involved in tumor progression. In 
this perspective, the gene encoding parathyroid hormone re­
lated peptide (PTHLH gene)/09”111 which appears to be 
mapped exactly within the 12p derived amplicon, may be 
considered a candidate. This gene, whose product is an on­
cofetal hormone with endocrine and probably autocrine/para­
crine functions,112 is specifically expressed (nuclear localiza­
tion) in seminomas113 and was amplified (together with 
KRAS2) in a human lung cancer cell line.114 Lately, prelim­
inary results from comparative genomic hybridization exper­
iments on a large set of primary testicular germ cell tumors 
allowed the identification of a similar 12pll.2-pl2.1 derived 
amplicon in a subset of these tumors (seminomas and non­
seminomas), thus supporting its assumed relevance in ma­
lignant testicular germ cell tumor development,116
NATURE AND ORIGIN OF TH E I(12P) ISO CH RO M O SO M E IN
TESTICULAR GERM CELL TUM ORS
Fluorescence in situ hybridization studies have raised dis­
cussions about the nature and origin of the i(12p) isochromo- 
some (and/or other 12p abnormalities) in testicular germ cell 
tumors. Using a chromosome 12 specific a-satellite probe 
(that is D12Z3) as a cytological indicator of the centro­
mere,116 it was found in several testicular germ cell tumors 
and derived cell lines that the size of the centromeric region 
of the i(12p) iso chromo some was either significantly smaller 
or larger than those of normal chromosome 12 homo­
logues.117 In general, isochromosomes are believed to consist 
of 2 identical arms joined by a centromere as a consequence 
of a transverse instead of a longitudinal division during mi­
tosis.118*119 However, fluorescence in situ hybridization and 
restriction fragment length polymorphism demonstrated mo­
lecular heterogeneity for 1 of the best known examples of 
constitutional isochromosomes in humans, that is the i(Xq) 
chromosome in Turner's syndrome.120»121 Rearrangements 
leading to the i(Xq) chromosome can, in fact, occur at various 
locations in the pericentromeric region, and some cytogenet­
ically presumed X isochromosomes with larger centromeric 
fluorescence in situ hybridization signals may involve dupli-
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Fig. 7. Results of multicolor fluorescence in situ hybridization using chromosome 12 centromere specific alphoid repeat pal2H8 (red) and 
12p-specific “paint” M28 (green) as probes on metaphase spreads of i(12p) negative testicular germ cell tumor. A, 3 copies of normal chromosome 
12 (arrows) and 3 marker chromosomes (marl to mar3) containing 12p-positive material. B } besides 3 copies of normal chromosomes 12 (arrows), 
2 ,12p positive chromosomes (m arl and mar2) are also present. Inset shows enlarged m arl,47
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Fig. 8 . Five different stages of marker chromosome, add(12)(pl3), in i(12p) negative testicular germ cell tumor. Chromosome 12 centromeric 
and p-ami specific sequences are visible in red and green, respectively. Arrows indicate 12pll-13 orientation of 12p sequences in this chromosome. 
Note that only 1 centromeric area (red) is present in each marker, whereas 12p-sequences (green) showed multiple copies.47
cations of substantial parts of the X chromosomal p arm.122 
Based on the considerably smaller or larger pericentromeric 
regions observed during fluorescence in situ hybridization 
analyses, it was suggested that i(12p) chromosomes may be 
formed via nonreciprocal centromeric interchanges between 
nonsister chromatids of homologous chromosomes.62 As a 
consequence, the i(12p) chromosome would not represent a 
genuine iso chromo some, since the 2, 12p arms are presumed 
to originate from different parental chromosomes 12. In con­
trast, however, 3 other molecular (that is restriction frag­
ment length polymorphism based) reports clearly demon­
strated that the overrepresentation of 12p arms in testicular 
germ cell tumors positive for the i(12p) isochromosome is of 
uniparental origin.61*102’123 Thus, the i(12p) isochromosome 
in testicular germ cell tumors probably constitutes a genuine 
isochromosome with genetically identical arms and it is most 
likely that this chromosome, when present in testicular germ 
cell tumors, originates from a mi sdivi si on of the centromere 
rather than from a translocation or a nonsister chromatid 
exchange.61
How the generation of additional chromosome 12 segments
in testicular germ cell tumors without an i(12p) isochromo­
some, which has also been shown to be of uniparental ori­
gin,61 is accomplished remains to be established. In this 
perspective premature chromatid separation, resulting in a 
disruption of the chromosome 12 centromeres as observed in 
a fluorescence in situ hybridization study of testicular germ 
cell tumors without an i(12p) iso chromo so me, may represent 
another example of mitotic error relevant in development of 
these tumors.47 Premature chromatid separation between 
sister chromatids usually leads to chromosomal instability 
and breaks. Therefore, this process may account for the gener­
ation of free 12p arms, which after subsequent chromosomal 
rearrangements may contribute to an overrepresentation of 
uniparental 12p derived sequences as found in testicular gem 
cell tumors without an i(12p) isochromosome.47
»
LO SS OF HETEROZYGOSITY
Newly developed molecular genetic techniques have made 
a considerable contribution to solid tumor cytogenetics. In 
particular, the use of polymorphic DNA markers to discrim-
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inate between chromosome homologues124’125 has added a 
new dimension to the analysis of solid tumors.117'126 Sets of 
informative polymorphic (for example dinucleotide or trinu­
cleotide repeat) probes allow for the screening of all human 
chromosomes to create a so-called allelotype, a molecular 
counterpart of the karyotype. By comparing tumor DNA with 
constitutive DNA from the same patient, chromosomal dele­
tions, imbalances and/or rearrangements can be detected. 
Loss of heterozygosity for a polymorphic marker on a specific 
chromosome in tumor DNA provides indirect evidence for the 
presence of a tumor suppressor gene (or anti-oncogene, which 
usually controls cellular proliferation processes in a negative 
manner),127 of which 1 allele is mutated or micro-deleted 
(and, thus, functionally ineffective) and the other allele is lost 
by a large chromosomal deletion. Therefore, loss of heterozy­
gosity represents the second hit in the 2-hit hypothesis of 
tumor development reported by Knudson, finally resulting in 
a total loss of gene function.67,128> 129 Alternatively, loss of 
heterozygosity may represent loss of only 1 normal copy of a 
tumor suppressor gene, causing a dosage effect. In this way 
nonrandom allelic losses have been detected in various (fa­
milial) cancers and in some cases has even led to identifica­
tion of the relevant tumor suppressor genes, for example 
RBI, WT1 and TP53 genes in retinoblastoma,130 Wilms tu- 
mori3i(i32 and the Li-Fraumeni syndrome,133 respectively.
LOSS OP HETEROZYGOSITY IN TESTICULAR GERM CELL
TUMORS
As described, testicular germ cell tumors usually have a 
hyper-triploid to hyper-diploid (that is peri-triploid) chromo­
some complement, and cytogenetic analyses of seminomas 
and nonseminomatous germ cell tumors have revealed a net 
loss of chromosomes during karyotypic evolution.30*64 Theo­
retically, assuming that the loss of chromosomes is a random 
process, a triploid cell (for example malignant germ cell) has 
a 1 in 3 chance to become hemizygous for a chromosomal 
region upon further loss of chromosomal material.123 Thus, a 
greater percentage of loss of heterozygosity of a chromosomal 
region suggests nonrandomness and would indicate an im­
portant, probably early, event in tumor pathogenesis.
Frequent deletions of the short arm of chromosome 1 
(lp)58*134-138 and the long arm of chromosome 12 
(12q)32*33*139»140 have been reported in testicular germ cell 
tumors. Studies of possible loss of heterozygosity related to 
the deletions on the lp  arm have yielded somewhat conflict­
ing results, ranging from loss of heterozygosity for enzyme 
markers found in 3 of 4 established cell lines136 and in only 1 
of 10 informative tumors (using 2 probes for lp)141 to absence 
of loss of heterozygosity in 12 testicular germ cell tumors.142 
Loss of heterozygosity was found at the lpl3, lp22 and 
lp31.2-32.2 regions in a study of 46 testicular germ cell 
tumors,138 and at the lq42-43 region in another study.140 
Clearly, more cases must be studied using a larger battery of 
lp specific polymorphic DNA markers before any firm con­
clusion can be made regarding the possible involvement of a 
tumor suppressor gene on chromosome 1 in the pathogenesis 
of testicular germ cell tumors.
Even more controversy exists about the presence of a tu­
mor suppressor gene on the long (q) arm of chromosome 12. 
Cytogenetically visible deletions in the 12q (especially 12ql3- 
22) region were reported to occur nonrandomly (frequency 
20%) in 65 testicular germ cell tumors,32 a finding that was 
not confirmed by others in even more cases.64 In a followup 
study molecular mapping of these deletions was done using 8 
polymorphic 12q loci in paired normal tumor DNA samples of 
45 patients with testicular germ cell tumors.143 Two regions 
with a high frequency of loss of heterozygosity (greater than 
40% for 1 or the other region) were identified as sites of 
candidate tumor suppressor genes, 1 at the 12ql3 and 1 at 
the 12q22 regions. Moreover, homozygous deletions were
noted in 1 tumor for the D12S7 and MGF loci (both in the 
12q22 region). Therefore, it was postulated that these 12q 
deletions may represent loss of genes that have a key role in 
the development of testicular germ cell tumors.143 However, 
other series of germ cell testis tumors did not show such a 
high incidence of loss of heterozygosity (less than 20%) on the 
12q locus despite using the same probes.123,141-142 Evidently, 
the significance of loss of genetic material on the 12q region 
during testicular germ cell tumor development remains a 
matter of debate and, therefore, requires further investiga­
tion. A substantiation of the importance of 12q deletions in 
testicular germ cell tumors was documented recently for the 
12q22 region in a panel of 66 DNA samples derived from 
tumor specimens or cell lines and their corresponding normal 
cells using 5 additional 12q markers.143 In view of the ho­
mozygous deletion of the MGF gene,143 and high frequencies 
of loss of heterozygosity at D12S12 (47%) and D12S218 (37%) 
loci, a putative tumor suppressor gene may be found in the 
vicinity of these loci, 2 of which (MGF and D12S12) are 
within a 700 kb, region in band 12qll,143
Nonrandom loss of heterozygosity of the 3p and l ip  arms 
has also been suggested to be associated with testicular germ 
cell tumors. Although no consistent cytogenetic evidence for 
deletions or other rearrangements exists for these chromo­
somal arms, 28% and 25% loss of heterozygosity for the 3p 
and llp l5  regions, respectively, were found in 31 testicular 
germ cell tumors,144*145 and 29% loss of heterozygosity was 
found for the lip  15 arm in 14 tumors.141 Accordingly, it was 
hypothesized that the mutual exclusion of 2 possible tumor 
suppressor genes and inactivation of either 3p or l ip  se­
quences may be important mechanisms leading to the devel­
opment of a major subset of testicular germ cell tumors.145 
The possible involvement of the lip  15 region in germ cell 
testis tumor development is intriguing because of its role in 
a variety of tumors, for example Wilms tumor146 and ovarian 
cancer.147*148 In addition, the Wilms tumor 1 (WT1) gene is 
mapped on the short arm of chromosome 11 ( llp l3 )131*132*149 
and this tumor suppressor gene has been suggested to have a 
role in the development of the urogenital system.150-156 Some 
recent molecular studies have confirmed that loss of genetic 
information from the short arm of chromosome 11 occurs 
frequently. Loss of heterozygosity of the lip  13 and l ip  15 
regions was observed in 39% and 31% of all 26 tumors in 1 
study.156 Involvement of the WT1 gene in susceptibility to 
testicular germ cell tumors and in their progression has been 
postulated.157 Nonetheless, no gross DNA rearrangements or 
deletions of the WT1 gene were detected using the WT33 
cyclic DNA as a probe.156 The percentages of loss of heterozy­
gosity for the l ip  13 and l ip  15 regions were in accordance 
with random loss in a peri-triploid cell. Consequently, loss of 
genetic information from the lip  arm does not seem to be 
crucial in the pathogenesis of testicular germ cell tumors of 
adults.145 Recently, studies confirmed loss of heterozygosity 
at the lip  loci in a number of testicular germ cell tumors158 
and a high frequency of loss of heterozygosity affecting the 
DCC gene (located at the 18q21.3 region) was shown to occur 
in all histological types of testicular germ cell tumors.159*100 
These authors concluded that loss of function of this gene 
may be an early event in the genesis of these tumors. Signif­
icant loss of heterozygosity affected the APC/MCC gene (lo­
cated at the 5q21 region), RBI gene (located at the 13ql4 
region) and WT1 gene (located at the l ip  13 region) in some 
testicular germ cell tumors. No loss of alleles was found at 
the 6p locus in a number of testicular germ cell tumors.101 
Loss of heterozygosity of the 9p locus in testicular germ cell 
tumors has been reported.162
SEQUENCE OF ANEUPLOIDIZATION AND I ( I 2P)
ISOCHROMOSOME FORMATION
Loss of heterozygosity studies have also shed some light on 
the sequence of 2 possible oncogenetic steps in testicular
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germ cell tumors, that is the processes of aneuploidization 
and i(12p) isochromosome formation. In general, the gener­
ation of an iso chromo some in diploid cells leads to loss of the 
chromosomal arm not included in the anomaly. Therefore, 
this will lead to loss of heterozygosity of genes on the q arm 
of chromosome 12. Subsequent aneuploidization may gener­
ate multiple identical copies of the unaffected chromosome 12 
homologue in the tumor cells. Alternatively, if aneuplolidiza- 
tion precedes the process of i(12p) isochromosome formation, 
no loss of heterozygosity of genes located on the 12q arm will 
necessarily occur. The latter possibility was shown to be 
likely, since restriction fragment length polymorphism anal­
yses of testicular germ cell tumors positive for the i(12p) 
isochromosome demonstrated that the formation of this iso­
chromosome does not lead to loss of heterozygosity of various 
loci on the q arm of chromosome 12,60 These data are in 
agreement with more recent reports of retention of heterozy­
gosity for more than 10 loci on the 12q arm in testicular germ 
cell tumors.61’62*123’141*142 Thus, i(12p) isochromosome for­
mation is not the initial step in the development of testicular 
germ cell tumors, since it must be preceded by aneuploidiza­
tion. Its generation does not lead to gross loss of material of 
the long arm of chromosome 12.60
TUMOR SUPPRESSOR G EN ES AND PROTO-ONCOGENES
Tumor suppressor genes. Few studies have reported the 
expression of tumor suppressor genes in testicular germ cell 
tumors. To our knowledge only the retinoblastoma (RBI) and 
TP53 genes have been studied in some detail. A correlation 
was found between RB 1 gene expression and differentiation 
in testicular germ cell tumors.163 Initially, this tumor sup­
pressor gene, which is constitutively expressed as a cell cycle 
regulator protein in all normal human tissues,164-165 was 
found to be causally involved in primary retinoblastoma, 
either by gene structure (that is partially or completely de­
leted) or expression (that is decreased) alteration.165”167 
However, inactivation of the RBI gene is also associated with 
the development of several other malignancies, including 
osteosarcomas and soft tissue tumors,130>166>168~171 small cell 
lung cancer,172 breast cancer173-174 and bladder cancer.175 In 
testicular germ cell tumors decreased expression of the RBI 
gene was found in all tumors (especially seminomas and 
embryonal carcinomas) tested, although no gross alterations 
of the gene were found at the DNA level.163 The presence of 
the RBI protein was demonstrated in differentiated malig­
nant cells from 14 of 15 teratocarcinomas, whereas undiffer­
entiated cells of any testicular germ cell tumor were negative 
for this protein. Apparently, changes in the expression levels 
rather than mutations of the RBI gene are responsible for 
the absent or decreased action of the gene product found in 
nondifferentiated testicular germ cell tumors.163
The expression of the TP53 tumor suppressor gene has 
been studied immunohistochemically in testicular germ cell 
tumors of adults. This gene exerts a negative regulatory 
effect on neoplastic cell growth176 but when mutated it can 
cause a dominant negative effect and promote tumor progres­
sion177 as found in a variety of tumors.95«178-180 The TP53 
wild type gene product is virtually undetectable by immuno- 
histochemical methods due to its short half-life and its low 
abundance in cells,181 However, levels of TP53 protein de­
tectable by immun ohis to chemistry may indicate the expres­
sion of an aberrant form of this protein,181 since mutation of 
the TP53 gene usually results in stabilization of its pro­
tein,182’183 Studies of TP53 in testicular germ cell tumors 
have yielded seemingly inconsistent findings. Although the 
majority of testicular germ cell tumors showed expression of 
the TP53 gene as detected by immunohistochemistry,184-190 
only 4 TP53 gene mutations were found among a large cohort 
of 79 tumors.191*192 Possibly, cellular (for example post-trans­
lational) alterations rather than intragenic TP53 mutations
stabilize the TP53 protein for immunohistochemical detec­
tion.189 All histological components of testicular germ cell 
tumors showed immunohistochemically detectable expres­
sion of the TP53 gene but only in the embryonal carcinoma 
constituents was TP53 expression increased significantly 
among stages I to III disease.189 In a recent study, over 
expression of the p53 gene was found in 67% of testicular 
germ cell tumors and over expression involved the wild type 
p53 protein in the cell nucleus.193 Amplification of the 
MDM-2 gene (located at the 12ql3-14 region) was found in 
some tumors, which may be the result of p53 regulation of the 
MDM-2 level.193
Proto-oncogenes, The expression of several proto-oncogenes 
in different histological types of testicular germ cell tumors 
in adults has been described in more detail compared to that 
of tumor suppressor genes. It is conceivable that the devel­
opmental-like differentiation (from seminomas to the rela­
tively more differentiated nonseminomas) in testicular germ 
cell tumors may be associated with significant changes in 
gene expression. Considering its localization on the short 
arm of chromosome 12, the K-RAS gene seems to be a likely 
presumptive candidate. K-RAS, like other (that is N- and H-) 
RAS genes, encodes for p21 proteins that are involved in the 
transduction of signals from activated receptors in the cellu­
lar membrane to the nucleus. Mutations in these genes, 
particularly those in codons 12, 13 and 61, lead to a consti­
tutive activation of the encoded protein.194’195 RAS muta­
tions have been shown to occur in a broad assortment of 
human neoplasms (including leukemias and solid tumors). 
Therefore, they are considered to represent 1 of many events 
in the multistep process of transformation.196 Amplification 
and enhanced expression of the K-RAS gene have been re­
ported to occur in testicular germ cell tumors and derived cell 
lines,33-197*198 which is in concordance with overrepresenta­
tion of 12p derived sequences in these tumors. Molecular 
studies on the incidence of mutations in codons 12,13 and 61 
of the K-RAS gene, as well as the H-RAS and N-RAS genes, 
have resulted in a series of somewhat inconsistent data, 
probably reflecting geographical influences and diversity of 
techniques for specimen preservation and testing. Neverthe­
less, a low incidence (less than 15%) of K-RAS and N-RAS 
gene (that is codons 12,13 and 61) mutations and the absence 
of such H-RAS gene mutations have been reported for most 
primary testicular germ cell tumors and their derived cell 
lines.199“205 Thus, it is unlikely that K-RAS, as well as N- 
RAS and H-RAS mutations are essential for initiation or 
progression of testicular germ cell tumors.
Several other oncogenes have been tested for their putative 
involvement in testicular germ cell tumor development. The 
c-KIT oncogene (or stem cell factor [SCF] receptor gene), 
which encodes a tyrosine kinase receptor that has a funda­
mental role in the regulation of early hematopoiesis, sper­
matogenesis and melano gene sis, has been found to be ex­
pressed significantly in seminomas only.163-206,207 Likewise, 
the SCF gene shows altered expression in testicular germ cell . 
tumors: 7 of 9 seminomas (78%) were positive, whereas 22 of 
31 nonseminomas (71%) were negative for c-KIT and SCF 
genes.206 Considering that expression of c-KIT is present in 
the normal testis but lost or decreased during differentiation 
from seminomas to nonseminomatous testicular germ cell 
tumors, it has been suggested that this oncogene may inter­
fere with differentiation in these tumors.207 Such an involve­
ment in the pathogenesis of testicular germ cell tumors has 
also been suggested for the SCF gene.206 Intriguingly, the 
SCF gene has been mapped to the long arm of chromosome 12 
at the q22 locus, a region presumed to undergo alterations in 
the pathogenesis of testicular germ cell tumors.
Similar findings and conclusions were reported for the 
c-MOS oncogene in testicular germ cell tumors, which is 
expressed at a high incidence in seminomas and embryonal 
carcinomas (both undifferentiated histological subtypes).207
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Conversely, the HST-1 gene product, which belongs to the 
family of human fibroblast growth factors, is absent in nor­
mal nonmalignant nonseminomatous testicular germ cell tu­
mors.113»163 An inverse relationship between expression of 
HST-1 and c-KIT oncogenes in testicular germ cell tumors 
has been suggested.163 The INT-2 gene, which is 61% homol­
ogous to the HST-1 gene, showed no expression.113 Several 
additional proto-oncogenes (L-MYC, c-MYB and INT-1) 
showed no expression in any type of testicular germ cell 
tumors, whereas others (c-RAF and c-FMS) were expressed 
in all types and in normal testis tissue.207
Other examples of significant differential expression of 
proto-oncogenes in adult testicular germ cell tumors have 
been described. N-MYC is expressed in more than 80% (20 of 
22) of the less differentiated histological types (that is semi­
nomas and embryonal carcinomas),207 In contrast, the rela­
tively more differentiated testicular germ cell tumors (that is 
immature teratomas) showed no N-MYC expression but re­
vealed a high level of c-ERBB-1 expression, which in turn 
(like c-ERBB-2) was absent or at minimum level in semino­
mas, embryonal carcinomas and normal testes.207 Another 
interesting finding was the type specificity of testicular germ 
cell tumors in the expression of the PTHLH gene, which is 
mapped to the short arm of chromosome 12.109-111 The on­
cofetal PTHLH gene was expressed in all 20 tumor samples 
containing elements of seminoma and choriocarcinoma but 
its product was not detected in embryonal carcinomas or 
teratomas as revealed by immunohistochemistry, in situ hy­
bridization and Northern blot analysis.113 Together, it has 
been amply demonstrated that the expression of several 
proto-oncogenes is switched critically during the differentia­
tion from seminomas or embryonal carcinomas to the more 
relatively differentiated nonseminomatous tumor types and, 
therefore, they may have important roles in differentiation of 
testicular germ cell tumors.
TESTICULAR GERM CELL TUMORS AND GENOMIC
IMPRINTING
Genomic imprinting, or gamete imprinting, is defined as a 
gamete specific modification (that is imprint) causing differ­
ential expression of the 2 alleles of a gene in somatic cells.208 
It was first identified as a bizarre form of chromosomal 
behavior in the homopteran scale insect Sciara.209 Before 
endogenous imprinted genes had been identified, the imprint 
was described as an epigenetic modification that was posi­
tively acquired in the germ line. Recently, CpG méthylation 
was investigated as a potential primary gametic imprinting 
mechanism.210-214 To date, 4 successive steps have been sug­
gested as being involved in the process of gamete imprinting:
1) acquisition of a primary imprint by either the male or 
female gamete, 2) maintenance of the imprint on 1 chromo­
some after DNA replication in the diploid zygote, 3) translo­
cation of the imprint in the somatic cells of the embryo into 
functional differences between the parental chromosomes 
(these differences may be accompanied by the acquisition of a 
secondary somatic imprint) and 4) erasure of the primary 
and secondary imprints in the germ cells of the next gener­
ation.215
Most of our current knowledge of mammalian imprinting 
comes from studies of mice, in which transgenes are differ­
entially modified and expressed in an allele specific way.216 
Several murine genes have been reported to show a unipa­
rental (that is mono-allelic) pattern of expression during 
normal development: 1119,217 igf2 receptor,218 igf2219*220 and 
Snrpn.221 In humans a role of gamete imprinting has been 
suggested for a growing list of pathological conditions.222' 224
Disturbance of the mono-allelic pattern of expression, re­
ferred to as relaxation of imprinting or loss of imprinting, has 
been suggested to have a role in several human solid tu- 
m o r s . 2 08 ’ 225-227 Loss of imprinting may cause activation of an 
otherwise transcriptionally repressed allele, thus resulting 
in over expression of that gene.208 If this gene encodes a 
growth promoting factor, the transcriptional activity of 2 
gene copies instead of 1 may lead to over expression of this 
factor, usually an important step in the genesis of solid 
tumors. Overrepresentation of certain chromosomal regions 
may also indicate the presence of genes encoding tumor pro­
moting factors. Since germ cell tumor overrepresentation of 
specific chromosomes does occur (for example chromosomes 
7, 8,12 andX), loss of imprinting on these chromosomes may 
have a role in the pathogenesis of these tumors.
Although overrepresentation of the short arm of chromo­
some 12, as found in testicular germ cell tumors positive and 
negative for the i(12p) iso chromosome, has been shown to be 
of uniparental origin in individual cases,G1 it may be of either 
maternal or paternal origin in different tumors,102,123 The 
absence of a preferential parental involvement of the 12p 
arm makes it unlikely that loss of imprinting on this chro­
mosomal arm is significant in the pathogenesis of testicular 
germ cell tumors.123 In contrast to chromosomal arm 12p, a 
preferential overrepresentation of the maternal chromosome 
22 (usually overrepresented in seminomas but underrepre­
sented in nonseminomatous testicular germ cell tumors) was 
found in 5 of 6 tumors, which may indicate the occurrence of 
genomic imprinting on this chromosome.123 In another report 
the allelic expression of the human H19 and IGF2 genes 
(both located on chromosome 11) essential for proper embry­
onal development,220,229 and known for their mono-allelic 
expression in mice and man,217-219*228' 231 has been studied in 
testicular germ cell tumors. Such tumors in adults originate 
from an early germ cell and to a certain extent mimic normal 
embryonal development.232 Therefore, it has been suggested 
that testicular germ cell tumors in adults may develop from 
precursor cells in which imprinting has been either erased or 
subjected to a consistent relaxation of its effect, The chromo­
somal constitution of these tumors,64>109 as acquired durin 
tumor progression, probably affects the developmental poten­
tial, and teleologie ally their histological constitution and bi­
ological behavior,232 If so, loss or relaxation of imprinting 
may be considered a primary (but reversible) event in the 
oncogenesis of testicular germ cell tumors, causing a cascade 
of disrupted differentiation and developmental processes 
that ultimately result in initiation and progression of testic­
ular germ cell tumors.
ONCOGENETIC MODEL
Although considerable insight into the biological nature of 
testicular tumors has been obtained during the last decades, 
the exact pathogenesis of testicular germ cell tumors is still 
poorly understood. Particularly, the histogenetic relationship 
between the morphologically and clinically distinct semino­
mas and nonseminomatous germ cell tumor types has been a 
matter of debate despite the fact that it is generally agreed 
that seminomas and nonseminomatous testicular germ cell 
tumors are neoplasms derived from primordial germ cells. 
According to the histological classifications originally devel­
oped by Friedman and Moore,233 and further refined by 
Dixon and Moore,234 seminomas are different from nonsemi­
nomatous testicular germ cell tumors, Seminomas recapitu­
late some aspects of spermatogenesis, whereas nonsemino­
matous testicular germ cell tumors represent descendants of 
pluripotential embryonic cells derived from germ cells 
through parthenogenetic activation.233«234 Consequently, 
seminomas and nonseminomatous testicular germ cell tu­
mors must have developed from germ cells along 2 unrelated 
pathways. Later, carcinoma in situ was recognized as the 
precursor lesion of seminomas and nonseminomatous testic­
i
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ular germ cell tumors.5’235 However, it was still unclear 
whether seminomas and nonseminomatous tumors develop 
directly through a multifocal process or, alternatively, 
whether they develop clonally from a single cell undergoing 
malignant transformation. The first concept assumes the 
derivation of seminomas and nonseminomatous testicular 
germ cell tumors (that is embryonal carcinoma, yolk sac 
tumor, choriocarcinoma and teratoma) from dysplastic intra- 
tubular germ cells through carcinoma in situ via 2 distinct 
pathways.8’75*235 The other concept, supported by recent his­
tological, cytogenetic and flow cytometric studies on semino­
mas, nonseminomatous testicular germ cell tumors and com­
bined tumors, and implying a close relatedness between 
seminomas and nonseminomatous testicular germ cell tu­
mors,17’37’71’72’236 suggests a single oncogenetic pathway for 
germ cell testis tumors.17»76»77’79’237’238 In this concept, car­
cinoma in situ is acknowledged as the precursor lesion from 
which seminomas and nonseminomatous testicular germ cell 
tumors develop, with seminoma as an intermediate stage in 
the transition from premalignant carcinoma in situ to malig­
nant, pluripotential embryonic cell-like nonseminoma (that 
is embryonal carcinoma). Although the latter concept has 
been favored recently, it is still unclear whether all embry­
onic carcinomas develop through an obligatory seminoma 
stage or whether direct transitions from carcinoma in situ to 
embryonic carcinomas (and other nonseminomatous testicu­
lar germ cell tumors) may occur as well.239
The number and sequence of oncogenetic steps leading to 
malignant testicular germ cell tumors are as yet largely 
obscure. Analogous to the multi-stage oncogenesis of skin 
and liver tumors,239»240 Damjanov postulated 3 distinct 
stages of testicular germ cell tumors (initiation, promotion 
and progression) in which progression represents the final 
stage in neoplastic development preceding the invasive 
growth phase of the tumors.239
Initiation. The process of initiation is largely un­
known74»239 and may represent a single hit, traceable to 
exposure to a carcinogen, virus or a genetic mutation.239-241 
No direct evidence for a higher (constitutional) chromosome 
instability was found in patients with (bilateral or familial) 
testicular germ cell tumors compared to the normal control 
population.242»243 Because of the presence of the X and Y 
chromosomes in testicular germ cell tumors, they are as­
sumed to be of premeiotic origin,236-244 so that initiation most 
likely occurs in primitive (that is diploid) germ cells. At this 
point it will remain dormant, until repeated promotional 
stimuli will invoke another oncogenetic transformation.239
Promotion. Promotion of initiated, or activated, primitive 
germ cells is another oncogenetic step that is poorly under­
stood. It is suggested that promotion can be achieved even 
after a prolonged latent stage has elapsed following initia­
tion, and that promotion evolves reversible epigenetic influ­
ences that must act until a stage of no return (that is trans­
formed germ cell) has been reached.239 If so, testicular germ 
cell tumors may be derived from activated germ cells at 
different stages. As already mentioned, loss or relaxation 
(and possibly other disturbances) of gamete imprinting has 
been hypothesized as an early event in the oncogenesis of 
testicular germ cell tumors,232 although it is unknown when 
precisely this process occurs in the development of the prim­
itive germ cells to mature sperm. It is tempting to speculate 
that, depending on the stage of activated germ cells (for 
example primordial germ cell or spermatogonia), distortion of 
normal gamete imprinting (in combination with other 
genomic abnormalities) eventually results in the generation 
of malignant testicular germ cell tumors (of juveniles, adults 
and elderly men) with distinct developmental potentials.
Progression. The transformation of promoted germ cells 
into pre-invasive germ cells is morphologically recognized by 
the presence of carcinoma in situ. Except for yolk sac tumors 
in infants, spermatocytic seminomas and some teratomas, all
testicular germ cell tumors pass through a stage of carcinoma 
in situ.239 Carcinoma in situ as well as invasive testicular 
germ cell tumors are consistently aneuploid, ranging from 
tetraploidy for carcinoma in situ in patients without invasive 
tumors245-247 to peri-triploidy for carcinoma in situ located 
next to corresponding invasive testicular germ cell tumors.39 
Therefore, it is conceivable that the process of aneuploidiza­
tion, already stated as another relatively early event in the 
pathogenesis of testicular germ cell tumors,17»60, G4>104 is 
somehow causally related to the generation of carcinoma 
in situ. Theoretically, aneuploidization may result from 
polyploidization/endo-reduplication, cell fusion or successive 
non disjunctions of diploid cells, although the latter mecha­
nism seems unlikely regarding the relatively high ploidy 
index of carcinoma in situ. It is unclear what exactly triggers 
aneuploidization.
Invasive growth phase. The peri-tetraploid and, thus, chro- 
mosomally unstable carcinoma in situ will eventually de­
velop into an invasive germ cell tumor and does not regress 
spontaneously, even with a 30 to 40-year latent period,248 
The malignant transformation of carcinoma in situ into an 
invasive germ cell tumor probably results from a combination 
of 3 chromosomal events leading to a net loss of specific 
sequences: 1) loss of chromosomes or chromosomal material, 
particularly from chromosomes 11, 13 and 18, leading to a 
selective growth advantage either by loss of tumor suppres­
sion genes or loss of the ability for terminal differentiation; 
249,250 2) retention or gain of chromosomes or chromosomal 
material, specifically chromosomes 7, 8, 12 and X, leading to 
a selective growth advantage, and 3) development of struc­
tural abnormalities resulting in multiplication of 12p seg­
ments, especially 12pll.2-12.1, via i(12p) isochromosome for­
mation or 12p tandem duplications, and possibly deletion of 
12q22 sequences, conceivably leading to proto-oncogene and 
tumor suppressor gene deregulation (fig. 4).64*104 Although the 
order of these events is not necessarily fixed for the malignant 
transformation of carcinoma in situ into a germ cell tumor, the 
presence of an i(12p) isochromosome (and other 12p abnormal­
ities) appears to be somehow decisive for the malignant poten­
tial of testicular germ cell tumors30’46’55*58,91 and, thus, can be 
used as a diagnostic marker for these neoplasms.55»57
Histogenetic differentiation. The transition of carcinoma in 
situ to embryonal carcinoma via seminoma as an intermedi­
ate stage is characterized by several additional genomic 
changes. Nonseminomatous testicular germ cell tumors have 
a lower ploidy level than seminomas as a result of continuing 
net loss of chromosomal material. Most strikingly, chromo­
somes 15 and 22 are significantly underrepresented in non­
seminomatous testicular germ cell tumors compared to the 
relatively less differentiated and aggressive seminomas.30,31 
These chromosomes may contain genetic information that, 
when lost, triggers the transition of a seminoma into a non­
seminomatous germ cell tumor. Moreover, differential ex­
pression of tumor suppressor genes and proto-oncogenes may 
be involved in the differentiation of testicular germ cell tu­
mors from seminoma into nonseminomatous tumors: 1) ex­
pression of the c-KIT (SCF receptor), SCF, c-MOS, N-MYC 
and PTHLH genes is absent (switched off) in relatively more 
differentiated nonseminomatous germ cell tumor types (ex­
cept in the pluripotential embryonal carcinoma cells); 2) 
TP53 expression is significantly greater in embryonal carci­
noma cells of higher malignancy grade (triggering further 
differentiation?), and 3) there is exclusive expression of 
HST-1, c-ERBB-1/2 and RBI genes (switched on) in relatively 
more differentiated nonseminomatous germ cell tumors, 
such as teratomas. These gene actions promote further dif­
ferentiation of invasive testicular germ cell tumors into em­
bryonic and extraembryonic tissues.
It is obvious that this list of oncogenetic steps and their 
underlying mechanisms in the pathogenesis of testicular
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germ cell tumors is far from complete, and comprises a mul­
titude of suggestions but just a handful of facts. Moreover, it 
is likely that other, particularly genetic, factors are also 
involved in the pathogenesis of testicular germ cell tumors as 
suggested by various studies, such as racial differences and 
geographical variation in incidence of these tumors,251 famil­
ial clustering of tumors252 and correlations with HLA sub­
types.241’252*253 Nevertheless, some oncogenetic features 
have a clear diagnostic impact. The occurrence of carcinoma 
in situ in the testis must be considered the initial sign of 
testicular cancer, since it may ultimately and inevitably lead 
to formation of testicular germ cell tumors. Reliable detection 
and dissection of carcinoma in situ (for example through 
micro-needle biopsy and/or fluorescence in situ hybridization 
studies on semen) may prove to be of presymptomatic impor­
tance. Moreover, the presence of 12p abnormalities in testic­
ular germ cell tumors as found by classical cytogenetic stud­
ies (i[12p] isochromosome), and even more evident by 
fluorescence in situ hybridization and comparative genomic 
hybridization techniques (12p overrepre sentati on) is a clear 
indication for the invasive potential of testicular germ cell 
tumors, demonstrating its malignant transformation from 
preinvasive carcinoma in situ. Although the underlying mo­
lecular mechanisms in the oncogenetic processes are as yet 
unknown, the identification and verification of these 12p 
abnormalities may have considerable impact on further fun­
damental and clinical studies.
CONCLUSIONS
It is apparent from our review that the genetic (and epige­
netic) events leading to the genesis of testicular germ cell 
tumors are complex, with the only consistent changes being 
the i(12p) iso chromo some or other involvement of the 12 p 
arm. However, the changes affecting the 12p arm appear to 
be relatively late in the development of testicular germ cell 
tumors and, thus, cannot be initiating events regardless of 
their role in the biology of testicular germ cell tumors. It is 
probable that, like adenocarcinomas of other origins (colon, 
breast, lung or prostate), the malignant process in testicular 
germ cell tumors requires a cascade of relatively many steps 
for the full development of the tumors and their potential.25,1 
These genetic steps will undoubtedly receive, as some of 
them already have, the attention of the molecular geneticist 
in establishing a reliable scheme into which the presently 
known changes, including the i(12p) isochromosome, will fit. 
Such a scheme may not only supply needed and cogent infor­
mation on the genetic events that lead from a gonocyte to the 
various types of testicular germ cell tumors but also infor­
mation of help to the clinician by enlarging the diagnostic 
armamentarium for such tumors, correlation of genetic pa­
rameters with prognosis and, ultimately, supplying informa­
tion on developing curative therapies (based possibly on spe­
cific genes affected), particularly in tumors that are resistant 
to present forms of treatment.
APPENDIX: CHROMOSOME CHANGES IN  TESTICULAR GERM CELL TUMORS (THE FINDINGS ARE ARRANGED ACCORDING TO
HISTOLOGICAL TYPE)
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46-47, XY, +del(20)(ql2)/46, XY, del(l)(q32)
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67-74, XXY, +Y, +7, +8, -11, +i(12XplO)x2, -13 , +14, +15, -18, der(20)t(3;20)(p24;pl2), 
+21
Neuroepithelioma
60-76(3n), XY, +X, +2, -3, -5 , -11, -11, -15, +21, +21, -22, -22, +derdl)t(ll;?Xq24;?), +der 
(Il)(?::pl5-q24::?), +i(12p), +dei<12)t(l;12Xqll;ql3), +dei<13)t(13;?)(pll;?), +der(15)t(15;?)(pll;?), 
+t(15;15)(pll;pll), +mai'lx2
Seminoma
53, XY, +3, +4, +6, +7, +11, +13, +19 
73, XY, t(l;4)(ql2;pl6), del(7)(q34), i(12p), ine
73, XY, t(l;8)(ql2;q22), 7q+, i(12p), t(15;15)(q26;q26), t(7;14)(pll;q31), ine 
81, XY, t(l;8)(pl2;qll), i(12p), ine
62, XXY, +1, +2, +del(3)(qll), +4, +7, +9, +i(12p), +15, +16, +16, +17, +20, +21, +mar 
113, XXXY, i(lq), t(7;?)(q22;?), i(7p), t(12;?)(ql3;?), t(12;?)(pll;?), i(17q), +5mar
64, XY, t(X;?)(p21;?), t(l;?)(pl3;?), t(l;?)(pll;?), t(7;?)(q22;?), dup(ll)(ql3q23), t(12;15)(pll; 
q ll), i(12p), t(13;14Xpll;pll), t(17;?)(q25;?), t(19;?)(ql3;?), t(20;?)(pl2;?), t(21;?)(pll;?), 
t(l;22)(pll;pll), ine 
69, XXY, del(l)(q31), i(12p), t(2;16)(q33;pl3), t(9;20)(p23;pl2), t(22;?)(ql3;?)
71, XXYY, t(9;?)(ql3;?), t(l;ll)(q21;q22), t(ll;?)(qll;?), t(ll;?)(pll;?), t(12;?)(q24;?), i(12p), 
t(16;?)(q24;?), i(17q), ine
72, XXY, t(l;4)(q21;q34), t(12;?)(pl2:?)
73, XXY, t(l;?)(pll;?), t(4;?)(q35;?), t(4;7)(q21;qll), t(4;7)(ql2;pl5), t(7;?)(q21;?), i(8q), t(8; 
?)(qll;?), t(9;?Xql2;?), t(ll;?)(q23;?), t(5;12)(q33;q24), i(12p), ine
104, XXXXYY, i(Xp), t(l;?Xq32;?), i(lq), i(2q), t(7;?Xq22;?), i(8q), t(12;?Xpl2;?), i(12p), ine 
106, XXX, t(l;?Xpll;?), i(2q), t(3;?Xp23;?), del(12Xq24), t(15;?Xq22;?), ine 
117, XXYY, t(X;?Xq28;?), t(l;15)(pll;qll), del(l)(pll)t(l;?Xp22;?), t(l;?Xqll;?), del(l)(qll), 
t(2;5)(q37;pl5), del(3Xq24), t(3;12Xp25;q24), t(5;7Xql3;q36), i(12p), t(14;?Xq24;?), ine
91, XXY, +1, +2, +2, +3, +3, +4, +5, +5, +6, +6, +6, +7, +7, +8, +8, +8, +10, +12, —13, 
+ 14, +14, +14, +15, +15, +16, +17, +18, +19, +19, +20, +20, +21, +21, +21, +21, 
+22, +9mar
69, XXXY, +1, +der(l)t(l;?)(lpl3 or p22;?), +2, +3, +6, +7, +7, +der(7)t(7;?Xqll;?), +8,
+8, +12, +der( 12)t(12;?Xp 13 ;?), +15, +15, +16, +19, +21, +21, +22, +2mar
46-48, XY, +18, +i(12p)
47-50, XY, +Y, -3, -4 , -9, -12, +15, +16, +17, +20, +del(lXpll), +del(4Xpl5), +der(9)t(9; 
?Xp24;?)
87-94<4n), XY, +X, +Y, -6 , -6 , -9 , -12, +22, +del(lXpll), +del(6Xql4), +del(6Xql6), 
+der(12)t(12;?Xpl3;?), +t(13;21Xpll;pll)
68-70, XXXY, +der(l)t(l;3Xp22;q21), -4 , -5 , +7, +8, -9 , del(10Xq23 or q24), -11, +dic(12; 
14Xpl3.3;q32), -13, +15, -17, -18, +19, -20, +21, +2-3mar
87-95, XXY, del(lXp21), +der(l)t(l;17Xp32;q21), +der(l)t(l;17Xp32;q21), -4 , +6, +add(7) 
(q22), +8, -9 , -9 , -10, -11, der(ll)t(ll;?X llpter^llq23::llq23-»llq ll::?), der(12) 
t(12;?13Xql5;?qll)x3, -13, -13, +14, +14, +der(14)t(14;21Xqll;pl2 or pl3), -18, +21, 
+21, der(22)t(9;22Xql2;pl3)x2, +mar
53-90(4n), XXYY, del(12Xql5), -19, -19, -20, +21, ine
60-76, XXY, +Y, der(l)t(l;4Xpl3;ql2), +3, -4 , -5 , add(6Xq23), +add(6)(q?), del(12)(pl2), 
der{14;14XqlO;qlO), -17, del(17)(pll), -18, +19, +21, +22, +hsr(?), +marl, +mar2, 
+3mar
70-89(4n), XXYY, -2 , -5 , del(6Xq21), -16, -17, -19, -21, +3-5mar 
90-106, XXYY, +X, +X, +Y, del(lXpl3), add(lXq21), +3, +5, add(6Xq21?), +7, +7, +8, -10, 
-11, del(HXq23), +add(12Xpl3), +add(12Xq24), +13, -16 , +17, -18, +19, -21, +22, 
+marl, +9mar
44-67, XXY, der(l)t(l;12Xpll;ql3), add(2Xp24), +add(3)(q21), -4 , -5, +del(6Xql3), +del(7) 
(q31), +del(7Xq31), -8 , -9 , -10, -11, del(HXq23), +der(12)t(ll;12Xql2;q23), -13, -14, 
-15, -16, -17, -18, add(19Xqll), -21, -22, +der(?)t(?;7X?;pll), +2-10mar
55-65, X, add(X)(q27), -Y, der(l)t(l;17Xpl0;ql0), +idic(lXpl3), -3 , add(3Xq24)x2, -4 , -4 , 
-5 , add(7Xqll), +der(7)t(3;7Xqll;p22), +8, +8, -9 , -9 , -11, -11, +i(12XplO)x2, -13, 
der(13)t(13;15Xq22;qll), der(14)t(3;?;14XqlO;?;qlO), -15, add(15Xpll), add(16Xq21), -17, 
-18, +19, -20, —21, der(21)t(12;21XplO;pl3), -22 , -22, +6-7mar
55-69, XXY, +add(lXp22), add(2)(q37), add(3)(p24), der(3)t(3;9)(p24;ql2), add(4)(q32),
der(4)i(4XqlO)add(4Xq35), +i(4XqlO), -5 , der(6)add(6Xql6)del(6Xp23), +add(6)(q27), 
+add(7Xpll), -9 , -10, -11, +12, +add(12Xpll), -13, +14, +15, add(16Xq21), -17,
— 18, -18, —20, +21, +add(21Xpl2), +l-5mar
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57-59, X, der(X)del(X)(p22)t(X;12)(q23;ql2), -Y, add(l)(pl3), add(l)(q24), -2~ +dic(3;22Xplï; 
p ll), i(3)(ql0)x2, -4 , dic(4;13)(q35;pl2), -5 , -7 ,  +8, -9 , -10, -11, add(12)(q24.1),
+i(12)(pl2)(pl0), -13, -13, dic(13;19Xpll;qll), -15, der(15)t(15;15Xpl3;qll), -16, -17,
— 18, der(20)(20pter^>20ql2::?::lq25—»Iq44::2q32—>2qter), —21, add(21)(pl2), der(21)t(21; 
21Xpl2;qll), der(22)t(7;22Xqll;pl2), +4-6mar
57-65, XX, -Y, add(lXpl3), +dic(l;4Xp34;pl6), add(3Xpll), -4 , -4 , -5 , add(6)(pll.l), 
add(7Xq21), der(8)t(7;?;8Xpl3;?;ql3), -9 , der(ll)add(llXq25)dup(HXql3q23), +12, 
+add(12Xqll), -13, -16, -18, -20, +21, -22
58-64, XXY, -1 , -2 , -4 , -5 , +6, der(6)t(2;?;6Xq24;?;ql2)x2, +7, +8, -9 , -10, add(ll)(pl5), 
del(HXq23), +i(12XplO), -13, -15, -17, -18, +2-6mar
60-63, XX, -Y, -3 , -4 , -5 , +7, +8, -9 , -10, -11, -13, -13, +15, -16, +20, -22
60-75, XY, -X, +Y, +add(l)(12), add(3Xpll), ~4, —5, +add(7)(q22)+trp(8)(ql3;q21.2), 
+add(10Xpl2), -11, +add(12Xq24), +i(12Xpl0)x2, -13, add(14Xq32), +15, add(16Xq24), 
-17, -17, -18, -18, +19, +der(19)t(9;19Xql2;ql3.4), +21, +21, der(?)t(?;14X?; 
qll)add(14)(q32), +mar
61-69, XXY, -2 , -2 , -4 , -5 , +del(6Xql5), +der(7)t(2;7Xq21;q36), +dic(7;?;12)
(7pter—>7q32::?::12pl3—*12qter), -9 , -11, -13, +14, -17, —17, —18, +21, +21, +mar
62-67, XXY, add(lXq32), add(lXpll), -4 , add(7Xq22), add(7Xq21), +8, -10, -11, -11, 
i(12XplO), -13, -15, -16, -17, -18, -20, +3-9mar
62-73, XXY, +add(lXpl3), -3 , -4 , -5 , +add(7Xq31), der(9)t(9;llXpl3;pll), -11, -11, +12, 
+i(12pXplO)x2, -13, -14, i(15XqlO), -16, add(16Xql3), -17, -18, +19, +21, +l-2m ar
63-66, XXY, add(lXq44), -2 , +3, -4 , -5 , +8, del(9Xq22), -10, -11, add(llXql4), add(12)(pl3), 
+i(12XplO)x2, -13, -13, -14, i(14Xql0), +15, der(17)t(7;17Xpll;pll), -18, +mar
63-68, XY, -X, +Y, dic(l;?;14Xpll;?;q32), -2 , -4 , -5 , add(6)(p23), +add(7Xq31), +8, +8, 
+der(8)t(7;8Xpl4;p22), -9 , der(9)t(9;9Xp24;qlO), -11, -11, +12, +i(12XplO), -13, -14,
-14, add(15Xpl3), -17, -18, +der(19)t(17;19Xq21;ql3), +idic(19Xpll), -22, -22, +4mar
66-69, XXY, +X, +Y, -4 , -5 , -6 , +7, -9 , add(9Xp24), -10, del(HXq21q23), der(ll)t(5;
HXql3;q23), +i(12Xpl0), -13, +14, +15, -18, +22 
68-70, X, del(XXq22), -Y, add(l)(p22), -5 , +add(7Xq32), +8, -11, der(ll)t(6;llX qll;ql4),
der(12)t(12;17Xpll;qll), +i(12XplO), -13, -14, -16, -16, -18, +20, +21, +21, +22, 
der(?)t(?;14X?;qll)
68-76, XXY, add(lXql2), +dic(l;12Xpl3;q22), -5 , +del(6Xq21q23), +7, +8, +8, -13, +14,
+ 15, —18, +21, —22, +l-7mar
69-74, XXY, der(l)t(l;16Xpl2;pll.2), add(3Xq24), -4 , -5 , +del(7Xpl2), +der(8)t(8;12XqlO; 
pll)x2, -9 , add(9Xq24), der(9)t(3;9Xql3;p24), -11, +12, -13, -15, -17, add(17Xpll.2), 
-18, add(18Xq22), add(19Xpl3.2), +21, +21, +21, +22, +der(?)t(?;12X?;pll), +l-2m ar
71-73, XXY, dic(l;?;9)(lpter—>lq42::?::9q34—*9pter), del(4Xq2?3), -5 , +7, +i(8XqlO), -9 , 
add(9Xq34), -11, inv(HXql3q25), +add(12Xq24), -13, +14, +15, +15, -16, -16, -17 ,
-18, +21, +21, +der(21)t(9;21Xqll;pll), +2mar
71-82, XXY, +1, +2, i(4XqlO), -5 , +6, +7, +8, +add(12Xpll), -13, +14, +15, +16, +19, 
-20, +21, +21, +22, +l-7mar
72-77, XXY, +Y, add(lXqll), +add(2Xql3), add(4Xq34), +der(4)t(l;?;4)(q23;?;q21)x2, —5, 
add(6Xq25), +7, +der(7)t(7;?;7Xpter-*qll.2::?::pl3-*pter), +8, +8, +10, -11, add(ll) 
(pll), der(ll)t(l;?;llXq23;?;q23), +12, +12, -13, -14, +15, +15, add(17Xq25), -21, +4mar
74-89, XXY, +1, +2, +del(3Xp21)x2, der(3)i(3)(pl0)dic(3;6Xp25;q27), +7, +7, +8, +8, +12,
— 13, +14, +15, +15, +19, +21, +mar
75-113, XXY, +Y, +1, +1, +der(l)t(l;14Xpll;qll), add(2Xp23), +3, add(4Xq34), -5 , +6, 
del(6)(q21q23)x2, +7, +7, +7, +add(7)(q32), +8, i(9)(ql0), +12, +12, +12, -13, -14, 
+15, +15, +add(16Xqll), +add(16Xql3), -18, +19, +19, +20, +20, +21, +8-16mar
Teratoma
56-62, XY, i(12p), ine 
69, XY, i(12p), ine
72, XY, i(12p), ine
92, XY, i(12p), ine 
95, XY, i(12p), ine 
99, XY, i(12p), ine 
102-105, XY, i(12p), ine 
67, XXY, i(12p), ine
56-62, XY, i(12p), ine (four cases)
60, XXY, i(12p), t(17;20)(q25;ql3), del(20)(ql3), 22p+, ine 
81, XXXYY, i(12p), ine
59-61, XXY, i(12p), ine 
77-80, XX, -Y, i(12p), inc
73, XXY, +1, +2, +3, +4, +7, +7, +8, +8, +9, +10, +t(ll;?)(q25;?), +12, +i(12p), +14,
+ 15, +16, +16, +17, +17, +17, +18, +19, +20, +21, t(22;?)(qll;?), +mar
59, XXY, i(12p)x2, +mar, ine
62, XXY, i(12p)x2, del(22)(ql2), ine 
71, XXYY, t(12;?)(pl2;?), t(12;?)(qll;?), i(12p), ine
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78, XX, -Y, i(12p), der(18), ine
87, XXY, der(5)t(5;?)(q31;?), inv(7)(pl5p22), der(7)t(7;7)(p22;qll), der(7)t(7;?)(pll;?), 
del(10)(pl3), der(ll)t(ll;?)(q25;?), del(12)(ql5q24), i(12p)x3, i(22q), ine 
126, X, -Y , +X, +X, i(12p)x2, ex
49, XY, +i(6p), +t(ll;12)(q23;qll), +i(12p), hsr(17)(pll)
61, XYY, i(12p), ine
66, XXY, i(12p), +l-5mar, ine
64, XXYY, del(10)(pl3), i(12p), dmin, hsr, ex
69, XY, t(X;2)(p22;q32), i(12p), t(9;14)(qll;pll), t(17;22)(qll;pll), t(10;12)(q26;ql3)
47-56, XY, +5, +6, +12, -16, +17, +19, +22, +hsr(l)(q44), +der(8)t(7;8)(qll.2;q24), 
+der(12)(?::pll-q24::?), +der(15)t(15;?)(pll;?), +der(16)t(16;?)(q24;?)
48-54, XY, +X, -Y, -1 , -5 , -5 , +8, -10, -10, +12, +17, -21, +der(l)t(l;?)(p36;?),
+del(5)(ql3), +der(7)t(7;?)(qll.2;?ABM), +der(10)t(10;?)(pl3;?), +del(12)(qll), +i(12p),
+der(12)t(12;?)(ql3;?), +t(14;21Xpll;qll)
48-64{3n), XY, -2 , -3 , -4 , -4 , -6 , +7, -9 , -9 , -13, -13, -14, -15, -18, -19, -20, -21, 
-21, +del(3Xp21), +del(3Xp23), + der(4)t(4;?Xq35;?), +del(5Xpl5), +i(12p)x3, +t(Y;
13Xpll;pll), +t(13;21Xpll;pll), +der(20)t(20;?Xql2;?)
48-75<3n>, XY, -2 , -5 , -6 , -8 , -10, -11, -13, +17, -19, -20, +del(6Xq21), +i(12p)x3
49-58, XY, +X, +1, +5, +7, -12, +17, +20, +21, -22, +der(l)t(l;?Xp36;?), +del(8Xql3), 
+der(12)t(12;?Xpl2;?), +der(12)t(12;?Xpl3;?), +marl?t(l:?:7Xq25:?:qll.2)
50-58, XY, +1, +2, +3, +3, +9, +12, +12, +13, +21, +del(5Xql3), +i(12p), +i(17q)
53-57, XY, +Y, +4, +12, +13, -16, +21, +del(lXp22), +del(6Xql5), +der(9)t(9;?Xpll;?),
+i(12p)x3, +mar
57-62(3n), XY, -1 , -6 , -10, -15, -16, -17, -18, -19, -22+del(6Xq21), +i(12p) 
57-66{3n), XY, +X, -1 , -5 , -6 , -6 , -10, -11, +12, +13, -16, -19, -20, +21, -22, 
+del(6Xq21), +i(12p)x2 
90-124<4n>, XY, +X, +X, +X, +Y, +2, +3, +5, +6, +8, +9, +11, +11, +13, +14, +15, +17, 
+ 17, +20, +21, +21, +21, +21, +22, +der(l)t(l;?Xp36;?), +del(5Xql3), +del(6Xq21), 
+del(7Xq22), +i(12p)x4, +der(17)t(17;?)(pl3;?), +l-2mar
100-116(4n), XY, +X, +X, +2, +3, +3, -5 , +9, +12, -18, -18, +21, +der(l)t(l;?Xp36;?), 
+der(7)t(7;?Xp22;?)x2, +i(12p)x4, +der(17)t(17;?)(pl3;?)x2, +mar
44-61(2n>, XY, +X, del(l)(q42), +2, +add(3Xp21), +del(6)(q25), +add(6Xqll), +7, +add(7)(qll.2), 
+del(7Xqll.2), +8, add(HXq25), +add(12Xpl3), -15, +16, +del(17)(pl2), +20, +21, +22
50-56, X, -Y, +X, +2, +3, +7, +del(8Xq21.2), add(HXq25), +del(12Xql4), +add(12Xpl3), 
der(13;14XqlO;qlO), +add(14)(q32), +r
l\/ín fì/vp fpvntnìyin
63, XXY, t(3;?Xp21;?), t(ll;14Xpl3;ql3), i(12p), ine
64, XY, +X, +Y, +1, +2, +3, +7, +7, del(7)(q31), +8, +9, +i(12p), +12, +13, +17, +20,
+21, +21, +marl, +mar2
64, XXXY, t(l;llXp34;ql3), t(l;llXql2;q23), i(12p), ex
52, X, -Y , +X, +6, +7, +7, -8 , +12, -14, +17, +21, -22, t(l;?Xp36;?), i(9q), +del(12Xq22), 
+i(12p)x3, hsr
54, X, -Y , +7, +7, -8 , -8 , -10, +13, +14, +17, -19, -20, +21, +22, +22, +t(l;?Xp32;?), 
+del(12Xql5), +i(12p), +l-2mar
69, XXXY, t(l;?Xp32;?), i(12p), ine
62, XY, +X, +2, +6, +7, +9, +10, +12, +13, -14, +17, -18, +21, +dic(X;l) (Xpter-> 
Xqll::?::lpl3-*lqter), +dic(l;21Xpl3;P13), +del(3Xpl3), +i(12p)x2+der(14)t(14;?Xpl3;?), 
+der(18)t(3;18)(pl3-14?;pll.3), +der(20)t(20;?)(pl2;?)
63, XY, +X, +2, +3, -5 , +6, +7, +8, +9, +10, +12, +13, -14, +17, +21, +21, +del(lXpll), 
+die(5;5Xpl5.3;pl5.3), +i(12p)x2, +der(14)t(14;?Xpl3;?), +der(20)t(20;?Xpl2;?)
47-50, XX, -Y, -1 , -2 , dic(3;15Xp21;pll), -4 , -5 , i(6)(pl0), +der(6)t(6;9Xp22;ql3), -7 , -9, 
-9 , -10, -10, -11, der(ll)t(ll;12Xq24;q21), -13 , -14, -15, -15, der(16)t(l;16Xql2; 
q21)add(lXq42), -18, -19, -20, -21, -22, -22, +der(?)t(?;14)(?;qll), +2mar 
67-70, XXY, t(3;14Xp25;ql3), del(6)(ql3ql5), +8, -9 , -11, +i(12Xpl0)x3, t(13;15XqlO;qlO),
-16, -18, +21, —22, +mar
R esidu a i m ature teratom a
53, X, -Y , +X, -5 , +7, +8, -10, +12, -18, +del(lXp34), +t(3;5Xq21;pl5), +t(7;?Xq22;?),
+t(10;?)(q26;?), +del(17Xpll), +2mar
59, XY, +X, +1, -2 , -2 , +7, +8, -9 , -9 , +10, -11, +12, +20, +t(2;?)(qll;?), +t(2;?Xpll;?), 
+t(2;3Xqll;pl3), +del(6)(q21), +del(7Xq22), +t(ll;?Xq22;?), +t(14;?)(pll;?), +4mar
54, XY, +X, +7, +8, -12, +17, +21, +del(lXp35), +der(12)t(12;?Xpl3;?), +i(12p)x2 
57, XY, +2, +3, +5, +7, +8, +12, +16, +17, +der(l)t(l;?Xp36;?)+i(12p)x2
57, XY, +X, +1, +5, +6, +7, +8, -9 , -10, +12, +17, -18, +20, +i(12p), +del(18Xpll), 
+der(9)(qll), +2mar
57, XY, +X, +1, +6, +7, -8 , +12, -14, +17, +21, +21, +der(l)t(l;?Xp34;?), +der(l)t(l; 
?Xpll;?), +del(8Xp22), +i(12p)x2, +2mar
58, XX, -Y, der(l)t(l;?Xp36;?), del(2Xq35), i(12p), der(17)t(13;17)(qll;q23), del(22)(qll), ex
65, XXY, del(lXq41), der(9)t(9;?)(pl3;?), i(12p), del(16)(pl3), ine
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Yolk sac tu m ors
59, X, -Y, +X, +1, +3, +8, +8, +8, -9 , +12, 14?, -14 , -16, +19, +19, +20, +der(9)t(9; 
?Xq24;?), +der(ll)t(l;ll)(q21;pl5), +der(ll)t(l;ll)(ql2;pl5)J + der(12)t( 12;?)(pl3 ;?),
+der(12)t(12;?)(qll;?), +mar4, +mar5
57-62<3n), XY, +X, +Y, -1, -2 , -5 , -6 , -7 , -8, -10, -11, -12, -12, -13, -14, -14, -15, 
-19, -20, -21, +del(l)(p22), +der(6)t(6;?)(q25;hsr::?), +der(ll)t(ll;?)(pl5;?)) +der(12)t(12; 
?)(pll;?), +i(12p)x2, +l-2mar/90/121{4n), XY, +X, +Yt +2, +3, +6, +9, -11, +16, +17,
+19, +del(l)(p22), +der(6)t(6;?)(q25;hsr::?), +der(ll)t(ll;?Xpl5;?), +i(12p)x3, +mar2 
59-62, XX, -Y, -2 , -4 , -5 , -6 , -7 , +8, +8, -9 , add(9Xq22), +11, der(ll)t(l;ll)(q21; 
pl5)x2, +add(12Xpl3), +add(12Xpl3), +add(12)(qll), -13, -14, -15, -16, -16 , -17, 
-18, +19, —21, -22, +2mar
M ixed  tum ors
Embryonal Ca/teratoma:
38-55, X, -Y, +7, -20, +22, +der(l)t(l;?Xp36;?), +del(5)(ql3), +i(12p)
47-52, XY, add(lXp31), +del(lXq23), +add(6)(pll), +8, -9 , +add(10Xpl3), +add(12Xpl3), 
+add(12Xq22), +add(7Xpl2), +21, +marl, +2mar
49-59(2n), XY, +X, del(lXp34), +del(lXq42), +2, +add(3)(p21), +del(6Xq25,)+add(7)(qlL2), 
+8, -10, der(10)t(10;?;10Xpl3;?;qll), +add(HXq25), +add(12Xpl3)s +13, -15, +16,
+del(17Xpl2), +21, +2mar 
Embryonal Ca/immature teratoma:
65{2n), XY, +X, +3, add(4Xpl4), +5, add(7Xqll.2), +add(7Xq21), +add(8Xq24.3)x2, 
+add(9Xpl3), +10, +10, +12, +12, +14, +add(15Xq22), add(16Xpl3.1), +17, add(18Xpll.2), 
+der(22)t(13;22Xpll.2;ql2), +r, +l-2mar
58, XXY, t(X;?Xp22;?), t(l;14X(pll;qll), t(2;?Xq37;?), del(9)(q22), i(12p), t(13;?Xql2;?), t(18; 
?Xqll;7), t(19;?Xql3;?), ex
67-123, XX, -Y, -4 , -9 , -10, -11, add(HXql3), +i(12XplO)x2, -13, -14, -18, +19, 
add(19)(ql3)x2, -22, +mar 
Embryonal Ca/mature teratoma:
60, XX, Y, t(2;?Xp23;?), dup(4)(ql2q21), t(l;llX qll;q21 or q23 or q24), i(12p), ine
51, X, -Y, +X, +1, +7, +8, +10, -1 , +19, +21, +22, t(5;?Xq35;?), t(9;?Kp24;?), +del(12) 
(ql3), +i(12p), +t(21;?Xq22;?), +t(l;21Xq21;q22), +mar
56, X, +X, -Y, +add(lXp36), +2, +6, +7, +8, +add(9Xqll), +dic(12;?;22Xpl3;?;pll.2),
+ 16, +17, +21, —22, +mar
56-60, XXY, add(lXq21), der(l)t(l;9Xq32;qll), dic(2;?;15)(pll;?;pl3), +dup(2)(q31q32), -4 , 
dic(5;22Xpl5.3;ql3), +del(6)(ql3), der(8)t(l;8Xqll;p23), -9 , t(9;13Xqll;q34), -10 , 
add(10Xpl5), -11, der(12)t(l;12Xq21;q24), +i(12XplO), -13, -13, del(14)(q23q2?4), -15, 
-15, -18, -19, +del(20Xql3), -21, -21, -22, -22 , +mar
59-68, XXY, -4 , -5 , -9 , -10, -11, +i(12XplO)x2, -14 , -18, -19, +21, -22
64-66, XX, -Y, add(lXp32), add(lXq31), +add(3Xpl4), -5 , +7, -10, -11, +add(12Xqll), 
+i(12Xpl0)x2, -13, -14, add(15Xq24), -19, -20, -21, -22, + l-6mar 
99-112, XXY, +Y, +1, +add(2Xpl3), +der(2)t(2;8Xq23;ql3), +3, +4, +5, +der(5)t(l;5Xql2; 
qll.l), +6, +6, add(7Xqll.2), +del(7Xqll.2), +der(7)t(7;8XplU;qll.l), +8, +8, +9, +10,
+ 11, +12, +12, +i(12Xpl0)x2? +13, +14, +15, +15, +16, +17, +der(17)t(17;18Xpll,?2;qll), 
+ 19, +20, add(20Xpll‘2)x2, +21, +22, +3mar 
Immature ter atoma/m ature teratoma:
59, XXY, del(lXp21), i(12p), t(l;lXp22;q21), ine
57-63, XXY, add(lXpl3), -3 , add(3Xq26), ~4, -5 , -7 , der(7)t(7;7;18) (7qter->7p22::
7ql1—>7q34: : 18ql 1—*18qter), +add(8Xp23), -9 , -10 , -11, -13, add(14)(q32), -15 , -18,
-18, add(18Xpll)> -20, -22 , +3mar
Mature teratoma/yolk sac tumor:
52-56, XXY, add(lXqll), +t(l;2)(ql0;pl0), -2 , add(3Xpl2), -4 , -5, -6 , i(7)(pl0), -9 , 
del(9Xqll), -10, -11, derdl)tdl;ll;9)(llpter-»llq25::llq25-»llql3::9ql3—>9qter), -13, 
add(13Xq21), +add(14Xpl2), -15, -16, -18, -19, -20, -21, -21, -21, -22, -22, +3-9mar
Mature teratom a/imm ature teratoma/yolk sac tumor:
52-58, XXY, -1 , -2 , -4 , -5 , -6 , dic(7;?; 13)(p22;?p 12), +8, -9 , -10, -11, i(12XplO), -13, 
-13, -16, -18, -19, -20, -22
57-67, XXY, +der(X)t(X;3Xq23;pl4), adddXqll), “ 4, -5 , +7, +8, -9 , -10, -11, 
+i(12Xpl0), -13, -13, -14, der(16)t(13;16XqlO;q24), -18, -19, +mar 
63-71, XXY, +Y, -5 , +8, -9 , -10, -11, +i(12XplO)x3, -13, +14, -18, -20, +mar
Embryonal Ca/immature teratom a/mature teratoma:
55, XY, +6, +7, +7, +12, +t(l;2Xp32;q35), +t(3;4?Xpll;pll?), t(8;?)(q24;?), t(ll;?)(q25;?), 
+t(17;?Xpll;?), +der(21)t(l;21Xql2;pll)
64, XXXXY, del(l)(p35), t(8;?)(q24;?), i(12p), t(15;?Xpll;?), ine
63, XY, +X, +2, +3, +5, +6, +7, +8, +12, +15, +16, +17, +17, —19, +der(l)t(l;ll)(p36;
ql3), +del(lXpl3), +del(7Xq31), +der(19)t(12;19Xpll;qll), der(20)t(9;20Xqll;pl3), 
+der(20)t(20;?Xpl3;?), +der(20)t(20;?Xpl3;?), +m3
63, XXY, t(l;llXp36;ql3), del(lXpl3), del(7Xq31), t(12;19Xpll;qll), t(20;?Xpl3;?), t(9; 
20Xqll;pl3), ex
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47-61, XXY, der(l)t(l;17)(p34;q21), add(2)(ql4), -4 , -5 , add(6)(ql5), +der(6)t(6;9)(ql2; 
ql2), add(7)(q21), del(8)(q24), -9 , -9 , -10, -10, -11, +i(12)(pl0)x2, -13, -15, -16, 
-18, -19, -22, + der(?)t(?; 10)(?;ql 1.2)
54-56, XX, -Y, del(l)(p21), -4 , -5 , -6 , +8, -9 , -10, -11, add(ll)(q23), del(12Xql3), 
+dic(12;15)(pl3;pl3), +i(12)(pl0)x2, -13, -14, -15, -15, dic(15;20)(q26;pl3), -16, -18, 
-19, add(19)(ql3), -20, -20, add(21)(q22), add(21)(q22), der(21)t(l;21)(p22;pl3), -22, 
+der(?)t(?;5)(?;ql3)
54-62, XXY, der(l)t(l;9)(p34;qll), -2 , -4 , -5 , -6 , -9 , -10, -11, +i(12)(pl0)x2, -13, 
-15, -18, -19, der(22)t(6;22)(pll;pll)
56-66, XXY, +Y, del(l)(p31), -4 , -5 , -11, der(12)t(2;12)(pl3;pl3), +i(12)(pl0), -13, -14,
-15, -18, -20, +21, +mar
57-67, XXY, -5 , del(7)(q34), -11, +i(12)(pl0)x2, -13 , add(16)(q24), -18, -19, -22, +mar
62-68, XXY, +der(l)t( 1 ;9)(p34;ql 1), +7, +8, -9 , -10, -11, dup(12)(ql3q21), +i(12)(pl0)x2, 
-13, -18, +19, +21, -22, -22
Embryonal Ca/mature teratoma/chorioca.:
49-60, XXY, -1 , der(l)t(l;l)(p36;q25), del(2)(ql?3), -4 , -5 , del(6)(ql3), -9 , -10, -11, 
+i(12)(pl0)x2, -13, -14, -15, -16, -17, -18, -19, -20, -22, +der(?)t(?;17)(?;qll),
+mar
Embryonal Ca/immature teratoma/mature teratoma/chorioca.:
66, XXY, t(6;?)(p25;?), i(12p), der(l)(qll), ine 
Embryonal Ca/immature teratoma/mature teratoma/chorioca./yolk sac tumor:
60-63, XXY, adddXpll), +add(l)(q32), der(2)t(2;?;9)(2pter-^2q24::?::9qll-^9qter), -4 , -5, 
der(6)t(6;14)(p22;q21), +7, -9 , -10, -11, add(12)(qll), +x(12)(pl0), +tas(12;13Xpl3; 
pl3), -13, -13, -14, -15, -16, -17, -18, del(18)(q21), -19, add(22)(qll), +2
61-65, XXY, -4 , -5 , +del(6)(q21q22), -9 , -10, -11, +del(12)(ql3), +i(12)(pl0)x3, -13, 
-14, -16, -17, -18, -19, +21, -22
61-66, XXY, add(3)(pl3), der(3)t(2;3)(pl3;p26), -4 , -5 , +7, -10, -11, +i(12)(pl0)x2, 
dup(13)(ql3ql4), -14, -16, -18, -19, +21, +der(?)t(?;ll)(?;pl0)
67-71, XY, der(X)t(X;2)(p22;q32), +8, -9 , +der(10)t(10;12)(q26;ql3), +i(12p)(pl0)x2, -13, 
+der(14)t(9;14)(qll;pll), -18, der(22)t(17;22)(qll;pll)
Embryonal Ca/immature teratoma/mature teratoma/seminoma:
110-116, XXY, +X, +Y, +Y, +1, +1, +2, +2, +3, +3, +4, +5, +6, +7, +7, +add(7)(qll), 
+8, +8, +8, der(9)t(6;9)(qll;pll), inv(9)(pllql3), +10, +11, +12, +12, +12, 
+i(12)(pl0)x2, +13, +14, +14, +15, +15, +16, +17, +18, +19, +19, +20, +20, +20,
+21, +21, +21, +22, +mar 
Embryonal Ca/immature teratoma/mature teratoma/seminoma/yolk sac tumor:
52-60, XXY, +add(lXp36), -2 , -4 , -5 , -7 , +8, add(9)(p24), add(9)(p24), -11, +12, 
+i(12)(pl0)x2, -13, -14, -15, -15, i(15)(ql0), -18, -20, -21, -22, +mar
61-65, XXY, +Y, +der(2)t(2;8)(q22;q22), -4 , add(4)(pl5.3), -5 , -10, -11, +i(12)(pl0)x3, 
-13, -14, der(15)t(8;15)(ql3;ql5), -16, -18, -19, -20, -22
63-68, XXY, +del(l)(pl3), +der(l)t(l;ll)(p36;ql3), -4 , +del(7)(q31), -9 , -10, -11, -13, 
-14, -18, -19, der(19)t(?12;19Xpll;qll), +add(20)(pl3)x2, +der(20)t(9;20)(qll;pl3),
—21, —22, +mar
63-68, XXY, +Y, -4 , -5 , +7, +der(8)t(8;9)(p23;ql2), -9 , -9 , -10, -11, +i(12)(pl0)x2, 
-13, —16, -18, —19, -20, +21, +21, +mar 
Embryonal Ca/immature teratoma/mature teratoma/seminoma/chorioca./yolk sac tumor:
59-63, XXY, add(lXpll), der(2)add(2)(p22)del(2)(q21), -3 , -4 , -5 , -6 , add(6)(ql6), 
+add(7)(q32), -9 , der(9)t(6;9)(qll;q21), der(10)t(9;10)(q21;q21), -11, +i(12)(pl0)x2, -13, 
-15, -16, -17, -18, -19, add(19)(pl3), -22, +mar 
Embryonal Ca/seminoma:
60, XY, +X, +Y, +2, +7, +8, +9, +9, +17, +der(ll)t(9;ll)(ql2;ql3), +der(17)t(l;17)(q23; 
q25)
47-63, XX, -Y, add(l)(p35), +der(l)t(l;12)(pll;ql3), add(2)(p24), -4 , -5 , +del(7)(q31), 
+del(7)(q31), -9 , -10, -11, del(ll)(q23), -12, der(12)t(ll;12)(ql2;q23), -15, -18, 
add(19)(ll), -21, -21, +rl, +r2, +der(?)t(?;7)(?;pll), +der(?)t(9;?;21)(ql2;?;qll)
Embryonal Ca/seminoma/ehorioca./teratoma:
55-57, X, +X, -Y, +der(l)t(l;2)(p22;q23), del(2)(q31), +3, der(6)t(l;6)(p22;q23), der(8) 
t(8;?;12)(8pter—»8q21.1::?::12?), +dict(8;9)(pll;ql0), add(10)(pl3), +der(ll)t(2;llXqll.2; 
pll.2)t(2;?)(q23;?), +12, +der(12)t(12;22)(qll;qll), +i(12p)x2, der(14)t(12;14)(?;pl2), 
+der(14)t(12;?;14)(14pter—ä>14q32::?::12?), -15, +17, der(18)t(15;18)(ql5;pll.2), add(19) 
(ql3.4), ider(22)del(22)(ql?), +l-3mar
Embryonal Ca/seminoma/chorioca./mature teratoma:
50-52, XXY, add(lXqll), der(l)t(l;9)(pll;pl2), +der(l)t(l;7)(pll;pl3), der(2)t(2;9)(p24;qll),
-3 , -4 , -5 , -6 , -7 , -8 , -9 , -9 , -10, -11, add(ll)(q25), +i(12)(pl0), -13, -14, -15, 
-17, -18, -19, -21, -21, -22 
Seminoma/embryonal Ca/teratoma:
45-72{2n), XY, +del(5)(q31), -9 , -10, +der(20)t(9;20)(ql3;pl3), +mar
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Seminoma/yolk sac tumor:
56-59, XXY, dic(l;6)(pll;q27), dic( 1 ;3)(p 13;ql2), add(2)(q33), der(2)add(2)(pl6)ins(2;?)(q31; 
?), -3 , -4 , -4 , -5 , add(6)(ql5), +add(7Xqll.2), -9 , -9 , -10, -11, -11, der(ll)t(ll;ll;9) 
(Ilpter-»llq25::llq25-*llql3::9ql2—>9qter), add(12)(pl2), 4-add(12)(qll), -13, -13, t(14;15) 
(ql0;ql0), -15, -15, -15, -16, -18, -18, -20, add(22)(ql3), +der(?)t(?;3)(?;pl4), +4- 
12mar
van Echten et al50
van Echten et al50
Gibas et al28 
Suijkerbuijk et al47
Atkin et al35 
van Echten et al50
Castedo et al31 
Rodriguez et al32
van Echten et al50
Rodriguez et al36
Rodríguez et al32
van Echten et al50
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Castedo et al31 
van Echten et al50
Castedo et al38
Castedo et al31
Seminoma/mature teratoma/embryonal Ca/yolk sac tumor:
68-75, XXY, -6 , add(6)(p25), +7, +7, +8, +12, +i(12)(pl0)x2, -13, +17, -18, -20, 
i(22)(ql0)
Seminoma/mature teratoma/immature teratoma/yolk sac tumor:
101—106, XXY, +X, +1, +add(l)(pll), +2, +3, +der(4)t(4j?6)(pl6jp21), +5, +6, +6, +7, 
+der(7)t(7;14)(q34;q22)} +8, +8, +der(9)t(9;12)(pl3;ql5)} +10, +11, +12, +add(12)(pll), 
+i(12)(pl0)x3, der(13)t(2;13)(pll;pl2), +der(13)t(5;13Xpl3;pl2), +14, +14, +15, 
+der(15)t(3;15)(pl3;pl2), +17, +add(17)(pll), +18, +19, +19, +20, +add(20)(ql3), +21, 
+22, +22, +2mar 
Seminoma/embryonal Ca/immature teratoma:
61, XXY, t(l;?)(p22;?), t(8;?)(q24;?), i(12p)x2, 13p+, t(l;8;18)(p34;pllp22;pll), ex 
58(2n), XY, +X, +1, +2, +3, +add(6)(ql3), +7, +7, +8, +add(12)(pl3), +14, add(15)(q25)J
+20, +21, -22, +mar 
Mature terato ma/seminoma:
62-67, XXXY, -2 , -4 , add(5)(pl5), -6 , -6 , -11, dic(12;13)(12pl3.2;q22), -13, -14, -18,
— 19 —20 -21 —22 +5-7mar
56-59, XXY, der(l)t(l;l)(ql0;ql0), add(3)(pl2), -4 , -5 , add(6)(p21), del(6)(ql3), -8 , -9 , 
-10, -11, +i(12)(pl0)x2, -13, -14, -15, der(17)t(5;17)(ql3;pl3), -18, -19, del(21)(q22), 
-22
56-60, XXY, +Y, +der(2)t(2;9)(q23;qll), -4 , -6 , -9 , del(9)(qll), -10, -11, +i(12)(pl0), 
add(13)(pll), -14, -15, -18, -19, -20, -22 
Embryonal Ca/yolk sac tumor:
57, XY, +X, +1, +2, +7, +12, -14, -20, +21, +del(7)(q32), +i(12p)x2, +der(13)t(13;14) 
(13pll::14qll—>q31), +del(17)(pll), +2mar 
52—62, XY, +X, —1, +3, +7, +9, +13, +14, +15, +16, +21, +del(l)(p32), +i(12p), +mar 
54-69(3n), XY, +X, +Y, -1, -5, -10, -10, -14, -15, +16, -17, +del(5)(ql3), +del(10)(pl3),
+i(12p)x2
54-55, XXY, -1 , -2 , -3 , add(3)(pll), -4 , -5 , der(5)t(5;ll)(q35;ql3), ~6, +der(7)t(7;
Il)(q22;ql3), -9 , -10, -11, del(ll)(q21q24), -13, -14, -16, -18, add(18)(q23), -19, 
-20, -21, -22, +3mar
55-60, X, -X, -Y, add(l)(pl3), -2 , -3 , dic(3;7)(3pter—»3q23::7qll.2—*7q31::7q31~*>7pter), 
-4, -5 , -6, -8 , add(8)(pll), -9, -10, -11, add(12)(q24), +i(12)(pl0)x2, inv(12)(ql5q24.1), 
-13, -14, -15, -16, -18, -19, -20, -22, add(22)(ql3), +3mar
56-62, XXY, +Y, -1 , -2 , -4 , -5 , -6 , add(8)(p21), -10, -11, +i(12p)(pl0)x2, -13, der(13) 
t(13;21)(pll;qll), -15, -16, -18, —19, —21, -22, +mar
59-63, XXY, +X, del(l)(p34), add(2)(p23), der(4)t(4;8)(q21iql3), -5, -9, -10, -11, -i(12)(pl0)x2, 
-14, -18, -19, -20, -22, +mar
Teratom a/embryonal Ca/yolk sac tumor:
46-60(2n), XY, +add(X)(p22), +add(l)(pll), +2, +3, +4, +6, +add(8)(q24.3), der(10)t(10; 
13)(q26;qll), +add(12)(pl3)x2, -13, add(15)(pll), +17, +20, +add(20)(pl3), +21, +22,
+mar
Immature ter atom a/embryonal Ca/yolk sae tumor:
51-66(3n), XY, +X, +Y, -4 , -5 , -9 , -10, -13, -18, -19, +i(12p), x2 
Immature teratoma/yolk sac tumor:
55-62, XX, + dic(X;?;?9XXpter—>Xq28::?::9p21-»9qter), -Y, -4 , -5 , -8 , -9 , -9 , -11, 
der(ll)t(9;llXql2;q25), +add(12)(pl3), -13, der(13)t(13;21Xpl3;qll), -15, -18, -21, 
-21, dic(?8;?8;21X8pter~*8q21::8ql3—>8q24.3::21q22.3—>21pter), —22, +2mar
Embryonal Ca/mature ter atom a/chorioca./yolk sac tumor:
60-63, XXY, +add(lXp22), -4 , -5 , -7 , +8, -9 , -9 , -10, -11, -13, der(16)t(9;16Xql2;
q22), -18, +mar 
Embryonal Ca/mature teratoma/yolk sac tumor:
59, XYY, inv(X)(pllp22), t(8;?Xq24;?), i(12p), +mar, ine
57-60, XX, +X, -Y, +1, der(l)t(l;lXlqter—>lq23::lp34.1-»lq23:)x2, del(2)(qll), -4 , -5 , 
+del(6Xql5), -7 , -9 , -10, +i(12Xpl0), x2, -13, -14 , -15, -16, -18, -19 , -20, -2 2
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